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Biomolecular Structure and Dynamics

Interactions between the glycosylated Gag protein of MuLV and murine APOBEC3:
Novel insight into how MuLVs counteract restriction factors
Chairperson: Leonard Evans, Ph.D.
APOBEC proteins have evolved in mice and humans as potent innate defences against
retroviral infections. APOBEC3G (hA3G) in humans and mouse APOBEC3 (mA3)
deaminate cytidine in single-stranded DNA which ultimately results in hypermutation of
newly synthesized proviral DNA. Other deaminase-independent mechanisms of
inhibition have been identified, such as directly inhibiting reverse transcription. Both
HIV and murine leukemia viruses (MuLVs) have evolved mechanisms to evade the action
of the APOBEC proteins. HIV encodes the Vif protein which binds to hA3G and
facilitates its rapid degradation through the proteasome. The mechanism(s) by which
exogenous MuLVs evade mA3 inhibitory activity is unknown.
Exogenous MuLVs encode a glycosylated gag protein (gGag) originating from an
alternate CUG start site upstream of the AUG start site of the Gag structural polyproteins.
gGag is synthesized to similar amounts as the structural Gag polyprotein in MuLV
infected cells but is glycosylated in the endoplasmic reticulum and undergoes distinct
proteolytic processing. The function(s) of gGag remain unclear, but eliminating its
synthesis through mutation markedly impedes in vivo replication of the virus with very
little affect on in vitro replication. Endogenous retroviruses have not been found to
express gGag and are tightly controlled by mA3. APOBEC3 proteins are expressed in
many tissues in the mouse but are not expressed in most in vitro cell lines. These
observations are consistent with a link between gGag expression and the evasion of mA3
by MuLVs.
Studies described herein demonstrate that gGag is protective against both cellular and
virion-associated mA3 in vitro and is protective against mA3 in vivo. While there was no
direct interaction between mA3 and gGag in an infected cell, gGag and mA3 are
localized in the same compartment in the virion and are able to be coprecipitated together
from lysed virions. G-to-A hypermutation is not a mechanism used by mA3 to inhibit
gGag-negative MuLV replication. Through an affect on reverse transcription, cellular
and virion-associated mA3 reduce viral transcripts in MuLV infected cells in a gGagdependent manner.

xii

Chapter 1- Introduction
1.1 Retroviruses
Retroviruses are RNA viruses that replicate through DNA intermediates and
ultimately are incorporated into the genome of the target cell. If this occurs in a germline
cell the retrovirus becomes a permanent component of the host genome that is passed
down to subsequent generations177. Over the course of evolution, the human genome has
been infected approximately 40,000 times such that about 10% of the genome consists of
retroviral sequences177. The majority of these sequences are no longer full length and do
not encode a functional retrovirus. However, several endogenous retroviral elements
function in important physiological roles such as transcriptional regulation of host
genes11,41,46,106

and

the

induction

of

placenta-trophoblast

fusion

during

embryogenesis45,61,160.
Retroviruses are positive sense (+) single stranded (ss) RNA viruses that replicate
through DNA intermediates generated by the viral polymerase which is termed reverse
transcriptase177. The viral RNA is comprised of two identical RNA genomes that are
incorporated into the virion and resemble a large polycistronic messenger RNA98.
Reverse transcription of the viral RNA results in the generation of DNA transcripts which
are ultimately integrated into the target cell genome as a provirus177. Once integrated, the
provirus can use the cell's transcriptional machinery to transcribe its genome into
messenger RNA177. From this RNA, the retroviral proteins are translated. The translated
proteins are assembled to create new retroviruses that are subsequently released from the
cell through budding, allowing for an infection of a new cell.
1.2 Murine Leukemia viruses
1

Murine leukemia viruses (MuLVs) are classified in the Baltimore classification of
viruses as Type IV (+) ssRNA, DNA intermediate retroviruses that are part of the
Retroviridae family and the gammaretroviral genus98. MuLV virions are also classified as
type C10, with a centrally located spherical inner core composed of the nucleocapsid (NC)
and capsid (CA) proteins10,98. The genetic structure of a typical MuLV RNA genome and
the location within a virion of the gene products it encodes is schematically depicted
below (Figure 1.1).

Within the core are: the RNA genome, reverse transcriptase (RT),

integrase (IN), protease (PR), and the tRNAPro primer98. The inner core is surrounded by
an outer envelope composed of a lipid bilayer that contains the transmembrane (TM) and
surface (SU) subunits of the envelope (Env) glycoprotein98. In contrast to other types of
retroviruses, type C particles appear to be assembled largely at the plasma membrane
during budding10. The approximate diameter of a mature MuLV particle is 120nm10.
MuLVs can be either endogenous (integrated into the host genome) or exogenous (passed
from one host to another)98. Further classification of MuLVs has been based on host
specificity or tropism. Ecotropic115 MuLVs infect only mice, and utilize the mCAT-1
receptor. Amphotropic81 MuLVs infect mice and cells of many other species using the
Pit-2 receptor. Xenotropic115 MuLVs, although endogenous to mice, can infect cells of
many species but do not infect mouse cells, and utilize the Xpr-1 receptor. Polytropic82
viruses can infect many species including mice and humans and also use Xpr-1 as a
receptor.

Interestingly, the Xpr-1 receptor in most mouse strains is functional for

polytropic viruses but not for xenotropic MuLVs102.

All of the receptors thus far

identified are multiple membrane spanning proteins102.
Murine leukemia viruses (MuLVs) were originally identified and named for their

2

Figure 1.1. Structure of a MuLV virion. The most inner part of a virion is known as
the core, which contains the RNA genome, NC, IN and PR surrounded by the CA. The
CA is surrounded by the MA protein, which helps anchor the lipid membrane of the
virus which contains the envelope proteins TM and SU. Figure credit: Dr. Leonard
Evans.
ability to cause leukemias in mice1,47,62,70,75,97,156.

The term has since been adopted to

represent a large group of mouse gammaretroviruses. Some MuLVs that cause
proliferative diseases in mice are named after their discoverers: Gross MuLV by Dr.
Ludwig Gross (1951)75 (lymphocytic leukemia); Graffi MuLV by Dr. Arnold Graffi
(1955)70 (erythroleukemia); Friend MuLV (F-MuLV) by Dr. Charlotte Friend (1957)62
(erythroleukemia); Moloney (M-MuLV) by Dr. John B. Moloney (1960)47 (lymphocytic
leukemia); Rauscher MuLV (R-MuLV) by Dr. Frank J. Rauscher (1962)156
(erythroleukemia); Kirsten MuLV (Ki-MuLV)

by Dr. Warner H. Kirsten (1967)97

(lymphocytic leukemia); and Abelson MuLV (A-MuLV) by Dr. Herbert T. Abelson
(1970)1 (B-cell leukemia).

3

1.3 The RNA genome
MuLV virions include a dimeric RNA genome125,198 which is contained within an inner
core98,135. The structure and organization the MuLV genome is depicted (Figure 1.2). The
viral RNA resembles a large mRNA (~8.3 kb) containing a 5' cap158 and is
polyadenylated at the 3' end73. The RNA genome begins with a 5‟ short terminal repeat,
R84,167, followed by a short region which is termed U583. Immediately downstream of the

Figure 1.2. MuLV genomic structure and organization. The proviral DNA is flanked by
two LTRs, both of which contain a U3, R and U5 region. Following the 5' LTR are signals
that function in primer binding (PBS), splicing (SD), dimerization of the RNA genome
(DLS), and packaging (psi). Next are the genes that code for internal structural components
(Gag), replication (Pol) and receptor recognition (Env). These are followed by a sequence
required for DNA synthesis (PPT) and an LTR which contains transcriptional regulatory
sequences. Transcription of proviral DNA into RNA ( ) leads to two major species, the
full-length genome, and the spliced mRNA that encodes the envelope polyprotein.
Translation of the full-length RNA yields the polyproteins (
) gGag, Gag and Gag-Pol.
Translation of the spliced mRNA yields the Env polyprotein. These polyproteins are further
processed by the viral protease ( ) to yield their mature forms (see text).
4

U5 is the primer binding site (PBS), which is complementary to the cellular tRNAPro

80

and is the start site for reverse transcription80. The splice donor (SD)170 site is after the
PBS but before the packaging signal (psi)119 and thereby avoids virion incorporation of
spliced env gene mRNA. The psi region provides the packaging signal for the virion
RNA and also contains the dimer linkage site (DLS) that is required for RNA
dimerization131,161. The next portion of the genome consists of the gag gene6 so named
because the major gene product was initially identified as a group specific antigen. This
gene, which partially overlaps with psi, encodes a polyprotein that is proteolytically
cleaved to yield the structural proteins: matrix (MA, hydrophobic p15gag)7,
phosphorylated protein (acidic pp12)143, capsid (CA, p30)142, and nucleocapsid (NC,
basic p10)60. Upstream of the gag methionine start site is an alternative leucine start site
that encodes another polyprotein, termed glycosylated gag (gGag, gp80gag)54. gGag is
translated in the same reading frame as gag but contains an additional eighty-eight amino
acids on its N-terminus and appears to undergo distinct post-translational processing
compared to the Gag polyprotein54. The gag gene is followed by the pol gene6 which
encodes the viral protease (PR, p14)146 reverse transcriptase (RT, p80)5, and integrase
(IN, p46)72. After the pol gene is the splice acceptor (SA) which, with the SD, generates
the spliced env gene mRNA. The env gene encodes the surface glycoprotein (SU,
gp80env)93, and transmembrane protein (TM, p15env)87. Following the env gene is the
polypurine tract (PPT)178 which is the initiation site for positive strand DNA synthesis.
After the PPT is the 3' (U3)31 region which contains the transcriptional regulatory
elements of the virus. The U3 is followed by the 3‟ short terminal repeat (R)84,167. The
U3 region and U5 region are so named because they are unique 3‟ and 5‟ sequences that

5

are incorporated along with the R region into the long terminal repeat (LTR) found in
proviral DNA.
1.4 Replication Cycle
1.4.1 Binding and entry
The outer subunit (SU, gp70) of the MuLV envelope protein is responsible for
recognition of cellular receptors85 and the initiation of infection.

The viruses are

classified into four groups originally based on the infectious host range of the MuLVs and
later shown to correspond to the utilization of distinct cell-surface receptors81,82,114. After
SU/receptor binding, the virus enters the cell through a pH-dependent endocytic

Figure 1.3. Replication cycle of MuLV. (1) Binding of viral envelope to cell
surface receptor. (2) Fusion and entry into the cell. (3) Uncoating of virion (4)
Reverse transcription yielding proviral DNA. (5) Preintegration complex enters
nucleus, integrates proviral DNA into host genome. (6) Transcription of provirus. (7)
Translation of virion components. (8) Assembly at the cell membrane. (9) Budding
of the virion. (10) Maturation and release of the virion. Figure credit: Jennifer
Kolokithas.

6

pathway92 and fuses with the membrane, a process that is dependent on the insertion of a
fusion peptide from the transmembrane (TM, p15Env) portion of the viral envelope into
the cellular membrane86. Upon fusion, the virus uncoats (viral core components separate
from outer membrane of the virion) and reverse transcription of the RNA genome
proceeds in the cytoplasm98,135.
1.4.2 Reverse transcription
The RNA genome serves as the template for the synthesis of the DNA provirus mediated
by the viral RNA-dependent DNA polymerase (RT). As illustrated in Figure 1.2, the RNA
genome which contains a 5' cap and is polyadenylated at the 3' end, consists of the R, U5
and PBS at the 5' end of the molecule, followed by the gag, pol and env genes, with the
PPT, U3 and R on the 3' end. The steps of reverse transcription are depicted
(Intermolecular model, Figure 1.4). First, the tRNApro binds to the PBS of the genome84.
From the PBS, using the tRNAPro as a primer, RT transcribes minus (-) strand DNA in the
3' to 5' direction ending at the R region5,84. The RNase H activity degrades the RNA
portion of the RNA/DNA hybrid71. The newly synthesized DNA (called the minus strand
strong stop DNA) coupled to the tRNA primer dissociates from the 5' end of the RNA
genome and hybridizes to the complementary 3' R region of the genome32,33. Minus
strand DNA synthesis continues to the PBS at the 5' end of the molecule while the RNase
H activity of RT degrades the RNA genome, except for the PPT region 44,178. RT uses the
PPT RNA as a primer to synthesize (in the 5' to 3' direction) the plus (+) strand of DNA
to the PBS carried by the strong stop (-) DNA, using the minus strand as a

7

Figure 1.4. Reverse transcription of the viral genome. 1). The tRNAPro binds to the
PBS of the RNA genome (
) and RT transcribes minus (-) strand DNA (
) in
the 3' to 5' direction ending at the R region. 2). RT's RNase H activity (
)
degrades the RNA portion of the RNA/DNA hybrid. 3). The newly synthesized DNA
and tRNA primer dissociates from the 5' end of the RNA genome and hybridizes to the 3'
R region of the genome. Minus strand DNA synthesis continues to the PBS at the 5' end
of the molecule while the 4). RNase H activity of RT degrades the RNA genome, except
for the PPT region. 5). RT uses the PPT RNA as a primer to 6). synthesize (in the 5' to 3'
direction) the plus (+) strand of DNA to the PBS contained within the strong stop (-)
DNA, using the minus strand as a template. The resultant strand is called strong stop
plus (+) strand DNA. 7). The tRNAPro primer, PPT RNA and all remaining RNA is
removed. 8). The PBS of the (+) strand can anneal to the PBS of the minus strand and
RT can further synthesize DNA 9). resulting in a double stranded proviral DNA genome.

8

template178. The resultant strand is called strong stop plus (+) strand DNA. The tRNAPro
primer, PPT RNA and all remaining RNA is removed, leaving complementary PBS single
stranded DNA at the ends of the newly formed DNA genome

104,195

. The PBS of the (+)

strand anneals to the PBS of the minus strand and serves as a primer for RT to further
synthesize DNA producing the proviral DNA genome flanked by two long terminal
repeats (LTRs) consisting of the U3, R, and U5 regions104,195.
1.4.3 Integration
The proviral cDNA is incorporated in a nucleoprotein complex termed the pre-integration
complex (PIC). The PIC contains the viral proteins IN, CA and pp1215,72. The function of
the CA and pp12 are unclear, however the IN plays a direct role in integration. The

1
IN

IN

2

3

-OH

-OH

-OH

-OH

CA
GT

-OH
-PO4-

CA

-OH
-PO4-

4

GT

5

6

Figure 1.5. Integration of proviral DNA. 1). The proviral cDNA becomes part of the preintegration complex (PIC). 2). The 3' ends of the DNA are nicked by IN to produce 3'
hydroxyl ends. 3). The PIC is then shuttled into the nucleus, which in the case of MuLVs
only occurs in actively dividing cells during dissolution of the nuclear membrane. 4). The IN
produces a 4-6 bp staggered cut in the host genome which acts as a target for the proviral
genomes free hydroxyl groups to integrate into. 5). The gaps left behind and the noncomplementary ends of the proviral genome are 6). repaired and removed, respectively.
9

process of integration is depicted (Figure 1.5). At the ends of the MuLV proviral DNA are
conserved sequences: 5'-AATG and CATT-3'16,66. The 3' ends of the CA are nicked by IN
to produce 3' hydroxyl ends16,66. The PIC is then shuttled into the nucleus where the IN
produces a 6 bp staggered cut in the host genome generating free phosphates which act as
nucleophilic targets for the proviral genome‟s free hydroxyl groups16,66. The remaining
gaps in the host genome are repaired and the overhanging sequences of the proviral DNA
produced by the IN are removed16,66.
1.4.4 Transcription of the provirus
The proviral sequence from the host genome is transcribed as a cellular gene by RNA
polymerase II and mediated by transcriptional control elements contained within the
proviral LTR42,76. The 5' LTR (specifically U3)39,40 encodes promoter sequences (TATA
box) that are recognized by cellular transcription factors leading to the synthesis of the
RNA viral genome76, which is 5' capped and 3' polyadenylated. The start of transcription
is the first nucleotide of the 5‟ R and the polyadenylation signal is near the end of the 3‟
R76. Some of the full-length RNA genome is spliced to produce env mRNA57. Both the
spliced and unspliced mRNAs serve as templates for translation of viral proteins.
Unspliced RNA is also transported to the plasma membrane where it is incorporated into
budding virions.
1.4.5 Translation and maturation
The full-length unspliced mRNA is translated to the gGag, Gag as well as the
Gag-Pol polyproteins while the spliced mRNA is translated to the Env polyproteins57.
The Gag polyprotein is targeted to the inner cell membrane by myristoylation of the
amino terminus of the polyprotein.

The Env polyprotein is targeted to the cell
10

endoplasmic reticulum and ultimately to the cellular membrane through glycosylation.
The polyproteins are further processed during virion assembly by the viral protease,
which exists as a zymogen on the Gag-Pol precursor21. The protease is activated by
dimerization of the Gag-Pol precursor and the cleavage of the protease from the Gag-Pol
precursors occurs in trans. The Gag polyprotein (NH2-p15-pp12-p30-p10-COOH)8 is
cleaved to produce the 4 major components of the internal structure of the virion. p15 (or
MA) has a neutral charge and is the most hydrophobic protein of the virus7. It is located
between the lipid bilayer and the core of the virion and retains the myristoyl group
acquired before cleavage of the Gag polyprotein. In the context of the polyprotein MA
functions to align Gag

at the plasma membrane during maturation157. The only

phosphorylated protein in the virion is the acidic pp12. It is thought to be localized to the
core, binds with low affinity to the RNA genome and may serve some regulatory role143.
The icosahedral shell of the viral core is composed of the neutral p30 (or CA)142 which is
the major structural protein of the virus. Bound to the genomic RNA is the basic p10 (or
NC), which is a major component of the ribonuclear protein complex 60. It has very high
affinity to the packaging signal and the DLS of the RNA genome60. The Pol polyprotein
is generated by cleavage of the Gag-Pol polyprotein and consists of NH2-p14-p80-p46COOH. The protease (p14, PR) is responsible for cleavage of the polyproteins into their
final, mature forms during budding from the cell146. Reverse transcriptase (RT, p80) is
packaged into the core of the virion and is responsible for reverse transcription of the
RNA genome upon infection of a target cell8. Integrase (IN, p46) is also incorporated in
the core of the virion and is responsible for integrating the proviral DNA that results from
reverse transcription of the viral RNA genome into the host DNA72. The Env polyprotein
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is produced from a spliced viral mRNA and is organized as NH2-gp70-p15Env-COOH6.
The glycosylated gp70 is the surface subunit (SU) of the envelope protein and is localized
on the lipid membrane of the virion93. It is responsible for the virus's host-range and
binding to the cellular receptor93. The transmembrane (TM) portion of the envelope is
responsible for anchoring the SU to the virion by disulfide linkage and also contains a
fusion peptide that is required for the virus to fuse to the membrane of a target cell 87. The
viral RNA is packaged as a dimer along with the tRNApro 98. Immature virions start to bud
from the cell while the protease is continuing to cleave the Gag polyprotein.146.
1.5 Pathology and the 5 prime leader sequence
Many retroviruses have been discovered because of their ability to cause disease
in animals1,47,62,70,75,97,156. Various strains of MuLV were discovered because of their
pathogenicity in vivo1,47,62,70,75,97,156. Many studies of these MuLVs using mutational
analyses or chimeric viruses have been aimed at determining the viral components
responsible for pathogenesis and in vivo dissemination. Figure 1.6 lists some of the
functions of the 5' leader sequence discerned from such studies. Among these are studies
of chimeric viruses between F-MuLV and M-MuLV. F-MuLV induces early hemolytic
anemia followed by erythroleukemia176 and M-MuLV causes lymphocytic leukemia116.
Molecular clones between M- and F-MuLV in which the LTRs of F-MuLV and M-MuLV
were exchanged resulted in an alteration in pathology. M-MuLV carrying the LTR of FMuLV induced erythroleukemia while F-MuLV carrying the LTR of M-MuLV induced
lymphocytic leukemia24. Another study revealed that the 5' U5-Gag-Pol region was
important for viral dissemination and disease in vivo, but not for replication in vitro174.
Later studies specifically mapped attenuation of disease using mutant F-MuLV
12

constructs. A mutation abrogating the expression of gGag attenuated disease in vivo but
the mutant was still able to replicate similarly to the wild-type virus in cell culture36. It
was also found that 6-7 weeks after infection the majority of the gGag mutants isolated
had reverted back to expressing gGag, indicating that the gGag mutations were under
strong selection in vivo36. CasBrE-MuLV is another ecotropic MuLV that was isolated
from mice and has been extensively studied because it causes a severe neurodegenerative
disease63-65,127,150-153. Constructs replacing the 5' leader (U5-Gag) sequence of CasBrE
with F-MuLV (CasFrE) showed a rapid acceleration of disease150. The sequences
responsible for this acceleration mapped to the N-terminus of gGag (construct

Figure 1.6. The 5' leader sequence of MuLV. The 5' leader sequence of MuLV has been
linked to many functions that are essential for retroviral replication and disease induction.
The boxes (
) represent the span of the sequence that has been identified to have a
certain function in the retroviral life cycle.
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CasFrKP)153. A mutant that abrogated the expression of gGag (CasFr-3+4) was unable to
induce neurodegenerative disease and showed reduced dissemination in vivo153. The
mutant virus also showed revertants after infection, suggesting again a strong selective
pressure for gGag expression153. It is noteworthy that the revertants did not restore the
original gGag but rather were second site reversions which introduced new initiation
codons downstream of the original gGag start site. Nonetheless, both the replicative and
pathogenic functions of the mutant viruses were restored. When mice were inoculated
with revertants the viruses replicated and induced rapid disease similar to the wild-type
virus151.
1.5.1 Glycosylated Gag
All exogenous MuLVs encode an alternate form of the Gag polyprotein that is
glycosylated (gGag)54,112,154. gGag was first recognized on AKR MuLV-induced tumor
cells as an antigen112. The glycosylated protein is translated from the same viral mRNA
as Gag but uses a CUG start codon that is upstream of the AUG start codon for
Gag54,65,133. The coding region of gGag also overlaps with those required for RNA
packaging, ribosome binding, IRES-dependent translation and pathological determinants.
The alternative start codon for gGag results in an additional 88 N-terminal amino acids
on the Gag polyprotein. These additional amino acids contain a signal peptide that targets
gGag to the rough endoplasmic reticulum for glycosylation where it is then exported to
the cell membrane65,147. The proposed glycosylation sites exist in the p15 and p30 regions
of the polyprotein. gGag has been reported to be cleaved near the end of the CA region,
producing two products that migrate between 55kD and 45 kD on an SDS-PAGE gel.
Some of the C-terminal cleavage product of gGag is secreted while a pool of the N-
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terminal portion adopts a type II integral membrane configuration(Ncyto, Cexo)65,147. Some
gGag is incorporated into the virion, but the specific amount has yet to be determined63.
The levels of Gag and gGag protein expressed in an infected cell are similar65. Mutant
viruses that lack gGag are able to replicate efficiently in vitro, however, in vivo gGag
mutants are severely limited in their ability to replicate63,65,121. Reversion is strongly
selected for in vivo suggesting an important replicative role for gGag. The role of the
gGag protein is unknown in viral replication, though it has been suggested that it is
required for efficient budding and release in vitro121.
1.6 Restriction Factors
All eukaryotes carry mobile genetic elements in their genomes177. Retroelements
are in the family of mobile DNA sequences that use RNA intermediates and reverse
transcriptase to insert into a new point in the genome. In many species these elements
make up a large amount of the total amount of genetic content (10% in humans)177 and
represent insertion events into host genomes caused by retroviral infections over the
course of evolution177. In some instances these mobile elements can insert themselves
into regions of the genome that affect the control of cellular growth177 which obviously
could be detrimental to the survival of the host. Exogenous retroviruses can also infect
and insert themselves into the genome of their host, in many cases causing proliferative
diseases37,38,117,171,194. Over evolutionary time, many species have evolved mechanisms to
limit or restrict active retroviral replication9,69. In many cases retroviral expression is
suppressed by methylation of promoter sequences9,69, however, there are also distinct
factors that function to restrict retroviral replication. These „restriction factors‟ operate
on many different aspects of the retroviral life cycle ranging from viral receptor blockade
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to viral RNA degradation9,69.
1.6.1 Fv1 restriction
One of the first restriction factors identified was Fv1 (Friend virus susceptibility
1) in mice118. It was found to control susceptibility to F-MuLV disease, but has since been
shown to affect other MuLVs. There are two different alleles for the Fv1 gene, Fv1b (in
Balb/c mice) and Fv1n (in NIH/swiss mice). N-tropic viruses replicate efficiently Fv1n
mice but inefficiently in Fv1b mice. Conversely, B-tropic viruses replicate efficiently in
Fv1b mice but not in Fv1n mice. Crosses between Fv1n and Fv1b mice are resistant to
infection by N- or B-tropic viruses, while some viruses are NB-tropic and cannot be
blocked by either Fv1 allele148. Viral tropism is determined by one amino acid (residue
110) in the capsid (CA)103. The restriction mechanism of Fv1, which is thought to be
related to an endogenous retroviral gag protein, is thought to involve prevention of the
preintegration complex (PIC) from entering the nucleus, however the exact mechanism
has yet to be fully elucidated155. Several human cell lines infected with N-tropic MuLVs
encapsulated by the vesicular stomatitis virus-G envelope protein are also resistant to
infection, but do not carry Fv1b. Interestingly, the viral tropism in these human cells was
determined by the same residue in the CA (residue #110) of MuLVs. This resistance was
initially referred to as Ref1 (Restriction Factor 1; human antiretroviral activity related to
Fv1)190,191 and was observed in cells of many different species. Through cDNA
expression library screening, the activity of Ref1 was connected to a protein, TRIM5α184.
The mechanism of this restriction is currently under investigation but is thought to be
similar to that of Fv1.
1.6.2 Fv4 restriction
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After the identification of Fv1, another gene, Fv4, was found to restrict certain
retroviruses in Japanese wild mice91,137. The ecotropic MuLVs (able to infect only mice)
use the murine cationic amino acid transporter (mCAT) as their cell-surface receptor for
infection. Mice with mCAT and Fv4, however, are resistant to infection by ecotropic
MuLVs. Fv4 was found to be a defective envelope (env) gene of a provirus expressed at
the cell surface88,89. The Fv4 gene product is able to bind directly to mCAT, preventing
ecotropic MuLV infection by receptor blockade89.
1.6.3 HIV-1, Vif, and the discovery of APOBEC3
Human Immunodeficiency virus-1 (HIV-1) has also been shown to be restricted to
certain cell types. Evidence of this first emerged with the study of an accessary protein of
HIV-1, virion infectivity factor (Vif). Viruses lacking Vif (HIV-1 ∆Vif) were unable to
spread in CD4+ T cells or macrophages as well as some transformed T-cell lines
(nonpermissive cells). However, these same viruses were able to spread in other T-cell
lines (SupT1 and Jurkat) and in permissive, nonhematopoietic cells (COS, HeLa, and
293T)180,197. One important observation made in these experiments was that
nonpermissive cells were able to produce HIV-1 ∆Vif virions, but progeny viruses from
these cells were unable to replicate in any target cell line regardless of whether it was
permissive or nonpermissive. One possible explanation for this phenomenon was the
existence of a host factor able to inhibit viral replication in the absence of Vif but
abrogated when Vif was expressed. Such a factor was eventually identified by using
subtractive hybridization techniques with two cell lines: CEM-S (permissive) and CEMSS (nonpermissive).

A gene was cloned that could convert permissive into

nonpermissive cells upon transfection and expression. This clone was CEM15172, which
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was later found to be a member of the apoplipoprotein B mRNA-editing, enzymecatalytic, polypeptide-like family termed human APOBEC3G (hA3G). The expression of
hA3G correlated with the permissiveness of cell lines.

Furthermore, virions from

nonpermissive cells infected with Vif-deficient HIV-1 were shown to incorporate hA3G
accounting for their inability to replicate efficiently in either permissive or nonpermissive target cell lines.
1.6.4 Human APOBEC3G
hA3G is a member of a family of cytidine deaminases that is restricted to certain
tissues that exhibit both RNA and DNA editing activity189. Members of this family
include activation induced deaminase (AID) and APOBEC1-4, with APOBEC3 having
several isoforms designated A through H35. These enzymes catalyze the deamination of
the C4 position of the cytidine base. APOBEC1 has been found to regulate cholesterol
and lipid metabolism129. Another family member, AID, is required for somatic
hypermutation and class switch recombination in germinal center B cells130.
A member of the APOBEC3 family, hA3G, has been identified as an inhibitor of
retroviral replication. A principal mechanism by which this occurs is through cytidine
deamination of single stranded (ss) DNA transcripts during reverse transcription. The
inhibitory activity of hA3G is dependent on two catalytic domains (CDs). CD1 mediates
RNA23 binding and incorporation into the virion and CD2 functions as the deaminase
active site134. Encapsidation of hA3G requires the nucleocapsid (NC) region of HIV-1
Gag186, and as few as 7 APOBEC molecules incorporated into a HIV-1 ∆Vif virion are
sufficient to inhibit the virus in the next round of infection200. The deamination-dependent
mechanism for hA3G is depicted (Figure 1.7). In the target cell, virion-associated hA3G
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introduces dC to dU mutations in the minus strand viral DNA formed during reverse
transcription185. These DNA strands may be degraded by apurinic-apyrimidinic
endonuclease or uracil DNA glycosylase201. Strands that are not degraded and serve as a
template for plus strand synthesis incorporate A residues rather than G residues at the
deaminated positions. Extensive G-to-A mutations render the provirus inactive.

Figure 1.7. APOBEC3 and G-to-A hypermutation activity. During assembly at the
cellular inner membrane, APOBEC3 is incorporated into budding virions. Upon a
subsequent infection of a target cell, APOBEC3 exerts its deaminase activity during
reverse transcription. The newly formed transcripts are deaminated. This can lead to
either integration of the mutated transcripts or recognition of the transcripts by cellular
enzymes that lead to transcript degradation. Figure credit: Jennifer Kolokithas.

Furthermore, hA3G appears to inhibit viral replication through deaminase-independent
mechanisms. One mechanism appears to operate through binding RNA via CD1,
sterically blocking the tRNALys3 primer binding during reverse transcription initiation77.
Another mechanism has been reported to be independent of the catalytic domains and is
mediated by binding of hA3G to the HIV integrase, further inhibiting the virus‟s ability to
replicate124. The promiscuity of the deaminase activity of hA3G requires it to be
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sequestered to the cytoplasm199. Cellular localization, however, is not the only
mechanism involved in controlling hA3G‟s activity. It associates with a high molecular
mass (HMM) ribonucleoprotein (RNP) complex in resting CD4+ T cells in the thymus29,
where hA3G bound to RNA is inactive29. In contrast, in circulating CD4+ T cells hA3G
associates with a low molecular mass (LMM) RNP complex where it is active. Mitogens
control the switch between HMM and LMM complexes183, though HMM complexes can
be artificially changed to LMM complexes by treatment with RNase A29. LMM hA3G is
not recognized by Vif, therefore LMM hA3G can restrict entering viruses whether or not
they encode Vif. The identification of HMM and LMM complexes was the first evidence
that hA3G can affect HIV-1 replication without being incorporated into the virion29
though the authors claiming this recently retracted their study. Unlike virion-associated
hA3G, the antiviral activity of LMM hA3G does not involve DNA editing, but rather
inhibits the production of reverse transcription product (Figure 1.8). Neither LMM- nor
HMM-associated hA3G is incorporated into virions. Only newly synthesized hA3G is

Figure 1.8. Deaminase-independent activity. APOBEC3 proteins have been found
also to inhibit retroviral replication through deaminase-independent activity, such as
blocking reverse transcription or integration. Figure credit: Jennifer Kolokithas.
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incorporated into virions, but is enzymatically inactive179 because of interactions with the
HIV RNA genome and Gag proteins, similar to what is observed in HMM complexes179.
As noted above, the binding of hA3G to the genome impairs the initiation of reverse
transcription179. Once reverse transcription begins, RNase H degradation of the RNA
releases hA3G allowing cytidine deamination of the minus-strand DNA substrate
produced from reverse transcription179.
1.6.5 Murine APOBEC3 and Murine Leukemia viruses
HIV-1 encodes a gene product, Vif, which counteracts the antiviral effects of
hA3G. Vif binds to the N-terminus of hA3G and recruits an ubiquitin ligase complex that
marks hA3G for destruction in the proteasome34 (Figure 1.9). Vif has also been shown to
impair the translation of hA3G mRNA128 and prevent encapsidation by binding to

Figure 1.9. APOBEC3 and
Vif. HIV encodes an
accessory protein known as
Vif, which can bind to
APOBEC3 during retroviral
assembly and lead to its
proteasome-dependent
degradation. This allows the
HIV virions to prevent
encapsidation and continue
to replicate. Figure credit:
Jennifer Kolokithas.

hA3G141. Similar to HIV and hA3G, MuLVs have evolved a mechanism(s) to evade the
action of mA3 and are largely insensitive to its actions13,18,43,100,110,145,162, however,
MuLVs do not encode a Vif like accessory protein. While there are 7 family members of
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A3 in humans, mice contain only one26. mA3 exhibits a number of differences from
hA3G. The deaminase activity of mA3 resides in the CD1 while the RNA binding and
encapsulation into the virion resides in CD278. As noted above the converse is true of
hA3G. Unlike hA3G, two splice variants (delta-exon 2 and delta-exon 5) have been
identified for mA3159,164. Different mouse strains express different amounts of each
variant as well as the full length protein159,164. Different inhibitory effects of these
variants on the in vivo replication of certain MuLVs have been reported but remain a
subject of debate159,164. Recent studies have identified mA3 as Rfv3164; a gene involved in
the resistance of certain mouse strains to the induction of acute erythroleukemia in adult
mice by the Friend virus complex of the F-MuLV and a replication-defective pathogenic
virus termed the spleen focus-forming virus (SFFV)164. The mechanism(s) by which mA3
affects replication of the Friend virus complex remain unclear and warrant further
investigation.

Deaminase-dependent and -independent mechanisms have both been

associated with mA3, though the exact nature of these mechanisms remains
unclear26,27,164.
It is unknown how exogenous MuLVs largely resist mA3 activity. It is of note that
APOBEC3 family members from both humans and mice inhibit endogenous LTR
retrotransposons/retroviruses. This includes Human Endogenous Retroviruses (HERVs),
murine intracisternal A-particle (IAP), and MusD sequences12,49,50. Interestingly, one
major difference between endogenous and exogenous (MuLVs) retroviruses in the mouse
is the absence of an alternate initiation sequence in endogenous retroviruses for gGag.
1.7 Significance
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Mice as well as other mammals contain a very large number of endogenous
retroviruses comprising about 10% of the genome177. Transcripts of these viruses are
expressed in a very controlled fashion throughout life and likely are involved in a number
of physiological processes49,50. Endogenous retrovirus replication may lead to insertional
mutagenesis as well as inappropriate expression of retroviral proteins, thus it is likely that
the host has developed mechanisms to control such replication. The evolution of several
restriction factors that act post-transcriptionally, such as the APOBECs, may reflect this
necessity. In contrast to replication competent exogenous MuLVs, all of which encode
gGag, no endogenous proviruses encode this protein and are controlled in part by mA34951,90,113

. Mutant viruses that lack gGag are able to replicate efficiently in vitro but are

severely restricted in vivo63,65,121. These observations are consistent with the possibility
that gGag may serve to evade the action of mA3. Some reports in the literature suggest a
direct interaction of mA3 with gag encoded proteins110,123,162,188, however, a direct
interaction between mA3 and gGag has not been investigated.
Elucidation of the mechanism(s) by which MuLVs evade the action of mA3 may
provide additional insight into the means by which mammals evade the action of
retroviruses. Furthermore, it is has recently been reported that exogenous MuLVs that are
resistant to mA3, pseudotype endogenous viruses and allow their transfer to cells of other
species52,53,55,56. This may be of particularly interest in light of recent reports indicating
cross-species retroviral infections from mouse to humans120,166,193.
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Chapter 2- Experimental rationale and pilot experiments.
The effects of hA3G on HIV replication have been tested by many experimental
methods, each with unique advantages and disadvantages. Many methods to examine the
effect of mA3 on MuLV replication have been adopted from studies with
HIV2,14,18,30,43,90,100,101,110,149,162,203. In addition, other approaches examining the effects of
mA3 and gGag on MuLV replication have been developed. This chapter discusses the
rationale for the methods used in experiments presented throughout this dissertation.
2.1 Selection and generation of cell types
At the onset of these studies nearly all reports dealing with the effects of mA3 on
MuLV replication examined the effects of transfection of MuLV and mA3 expression
vectors in the 293T human embryonic kidney stem cell line transformed with the SV40
large T antigen2,18,43,110,162,188,203. There are a number of potential difficulties with this
approach. First, it is unclear if protein processing in this human cell line parallels that
observed in mouse cells202. Further, because of variation in transfection efficiency, the
expression of these vectors may vary from cell to cell and from experiment to
experiment. In addition, this approach is limited to examining virion-associated mA3
rather than the effect of cellular mA3 on virus infection. In this regard, primary bone
marrow-derived dendritic cells from mA3 knockout (KO) mice are more susceptible to
infection by MuLVs than their mA3-expressing wild-type (wt) counterparts123 . To
circumvent some of these difficulties stable mouse cell lines expressing mA3 were
developed. The lines chosen were NIH3T3 (3T3) and Mus dunni cells which do not
constitutively express mA3 as determined by quantitative PCR (qPCR) analyses (data not
shown).
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To generate stable cell lines expressing mA3, a pcDNA3 plasmid encoding the
full length mA3 derived from the Balb/c mouse strain and tagged at the C-terminus with
hemagglutinin (HA)18 was used to transfect the cell lines which were subsequently
selected in geneticin (G418). As no suitable antibody to mA3 was available, experiments
involving immunoblotting and immunoprecipitation required the use of a tagged version
of mA3.
2.2 Selection of MuLVs
To study the affects of gGag on viral replication in mA3 expressing cells, the
CasFrKP and CasFr-3+4 MuLVs were chosen. CasFrKP (gGag+) is a MuLV derived from
the wild mouse ecotropic virus CasBrE and contains a short sequence of the F-MuLV,
FB29, which includes the initiation site of the gGag protein152. CasFr-3+4 (gGag-) is a
derivative of CasFrKP in which two mutations have been introduced to disrupt the
initiation site of gGag at the -3 and +4 positions of the Kozak consensus sequence153.
These MuLVs have been studied extensively to determine the role of gGag in
pathogenesis as well as in in vivo and in vitro replication30,58,63-65,151,153. It has been
established using gGag-specific peptide antibodies that gGag is expressed in infected
cells and that an N-terminal cleavage product of gGag is incorporated into the virion63.
2.3 In vitro infectivity assays
Most studies that have examined the effects of human APOBEC3G (hA3G) on
replication have focused on the action of virion-associated hA3G upon infection of naïve
target cells17,20,22,23,34,77,96,100,124,126,128,132,179. However, the results of one study suggest
that cellular hA3g can inhibit infection by HIV virions early after entry29. It was of
interest to study the effects of both cellular mA3 and virion-associated mA3 on MuLV
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replication and determine if either exerted its effect in a gGag-dependent manner. In
order to examine the effects of cellular mA3 on viral replication, gGag+ or gGag- viruses
harvested from cell cultures that did not express mA3 were used to infect both cells that
express and cells that do not express mA3. Infectivity was quantified using either a focal
immunofluorescence assay (FIA) or assays in which a reporter gene was expressed. To
analyze the effects of virion-associated mA3 on replication, gGag+ or gGag- viruses were
harvested from cell cultures expressing mA3.

The mA3-containing viruses were

compared to viruses harvested from cells that did not express mA3 by their infectivity of
Mus dunni cells. Infectivity was quantified using either the FIA or reporter assays and
the data was normalized by RT activity of the virions in the supernatant as well as p30
quantification in order to deduce the specific infectivities of the viruses.

Figure 2.1. In vitro assay system. To test the effect of cellular mA3 on MuLV
replication, gGag+ or gGag- MuLVs were used to infect cells expressing or not
expressing mA3 (Initial infection). To test the effect of virion-associated mA3 on
MuLV replication, gGag+ or gGag- MuLVs produced from cells expressing or not
expressing mA3 (Initial infection) were used to infect Mus dunni cells (subsequent
infection).

26

2.3.1 Focal immunofluorescence assay
This assay175 exploits the display of virally encoded proteins on the surface of
infected cells. Using antibodies specifically reactive to the viral proteins, infected cells
decorated with the antibody can be detected either by direct conjugation of a fluorescent
dye to the antibody or, more commonly, by detection using a fluorescently conjugated
second antibody directed at immunoglobulin (Ig). Sparsely seeded cells are exposed to
the virus and allowed to grow to confluence. An infectious event can be quantified by
counting focal areas of infected cells that arise either from virus spread or by replication
of an initially infected cell.

Figure 2.2. Focal immunofluorescence assay. The FIA methodology takes advantage of late
stages in the viral replication cycle. During assembly of virions at the cell surface, infected
cells can be detected by labeling viral specific antigens with antibodies. This can be done
with directly conjugated antibodies specific for viral antigens or with labeled secondary
antibodies specific to the Ig that was used to bind to the viral antigen. Inset: A focus of
infected cells. Figure adapted from http://www.nimr.mrc.ac.uk/research/kate-bishop by Kate
Bishop, used with permission.
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Initial studies using the FIA examined the effects of cellular mA3 on infectivity of
MuLVs and on cell-free passage of viruses on cell lines.

The effects of cellular mA3

were performed by comparing virus titers in normal cell lines and in cell lines expressing
mA3. Both 3T3 cells and Mus dunni cells were examined and in both cells lines a
significant reduction in infectivity was observed with the gGag-deficient virus in cells
expressing mA3 (Figure 2.3).

Figure 2.3. Cellular mA3 and infectivity. A). 3T3 or 3T3/mA3 cells were infected
with gGag+ or gGag-. When the cells reached confluence (~4 days), infectivity was
quantified using the FIA with mAb 667 (envelope specific) and a fluorescently
labeled secondary antibody. B). Mus dunni or Mus dunni/mA3 cells were infected
with gGag+ or gGag- MuLVs and assayed as described in A).
2.3.2 Passaging of viruses on mA3 cells
In vivo studies of CasFr-3+4 as well as other gGag-negative MuLVs revealed a
marked selection for second site revertants that expressed gGag121,151. Considering that
the initial experiments suggested that gGag facilitates replication in the presence of mA3,
it is possible that mA3 is an important component of the in vivo selection for gGag and
that similar revertants might be generated in the in vitro system.

If revertants were

generated in vitro, one might expect them to persist in the mA3-expressing lines after
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extended passage. To examine this possibility, serial cell-free passages of the gGag+ and
gGag- viruses were performed on normal and on mA3-expressing cell lines.

Figure 2.4. Cell free serial passage of gGag+ and gGag- on mA3 -/- and mA3 +/+
cells. A). 3T3 and 3T3/mA3 cells were infected with each virus. 56 hours post
infection the supernatants were transferred onto uninfected 3T3 and 3T3/mA3 cells.
At the time of each transfer (pass) the supernatants were also transferred to Mus
Dunni cells and assayed for infectivity. B). Mus dunni (Dunni) Mus dunni/mA3
(Dunni mA3) cells were infected with each virus. 56 hours post infection the
supernatants were transferred onto uninfected Mus Dunni and Mus dunni/mA3 cells.
At the time of each transfer (pass) the supernatants were also transferred to Mus
dunni cells and assayed for infectivity. Each experiment was repeated twice with
three replicates.
The passage experiments revealed no evidence of selection for effective
replication in mA3 expressing cells. Indeed, in cells expressing mA3 the gGag- MuLV
was virtually undetectable by passage four. In contrast, in passage experiments using cells
not expressing mA3, the gGag- virus persisted albeit at somewhat lower levels than the
wild-type virus.
2.3.3 Reporter assays
The FIA requires amplification of the initially infected cells, either by virus
spread or cell replication, for efficient detection of focal infections175. The foci of the
gGag- virus on mA3 cells were smaller and more difficult to quantify than those observed
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on cells devoid of mA3. Thus the difference in the number of foci scored in the FIA may
have been due to differences in the initial infection of the cells or, alternatively, inhibition
of virus spread occurring subsequent to infection. Infectivities of retroviruses are
frequently quantified using retroviral vectors encoding a gene, such as alkaline
phosphatase or β-galactosidase, whose expression is detectable in the infected target cells
(reporter vectors). Reporter vectors generally include retroviral LTRs, promoters, and a
retroviral packaging signal in addition to the reporter gene. They resemble a viral
genome but do not encode viral structural proteins, thus infection by virions containing a
reporter vector does not result in a productive infection capable of spread subsequent to
the initial infection. Foci scored using these viruses are developed by cell division and
reflect the number of initial infectious events.
There are a number of procedures to generate retroviruses that have packaged
reporter vectors. The viruses can be generated by co-transfection of plasmids encoding
virus structural proteins with plasmids encoding a reporter vector. Alternatively, cell
lines harboring a reporter genome can be infected with a MuLV resulting in the release of
virions which have incorporated the reporter genome as well as the wild-type viral
genome.

Two reporter genomes were utilized in these studies: LAPSN (Clontech

Laboratories, Inc.) which encodes alkaline phosphatase and is expressed in the cytoplasm
of infected cells and G1nβgSVNa92 which encodes β-galactosidase expressed in the cell
nucleus.

Assays using either of these vectors yielded results similar to the FIA

experiments suggesting inhibition of infectivity by cellular mA3 in a gGag-dependent
manner.
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Figure 2.5. Reporter gene assay. The reporter gene assay allows for the detection of
infected cells through a non productive infection. The reporter genome is transcribed and
integrated into the host genome, but does not encode viral structural proteins, and
therefore expresses only the reporter enzymes. In the case of the LAPSN reporter
genome, alkaline phosphatase is expressed and activity is detected in the cytoplasm.
G1nβgSVNa encodes β-galactosidase that is expressed in the cell nucleus. Inset: Top: A
focus of cells infected with MuLVs harboring the LAPSN reporter genome. Bottom: A
focus of cells infected with MuLVs harboring the G1nβgSVNa reporter genome. Figure
adapted from http://www.nimr.mrc.ac.uk/research/kate-bishop by Kate Bishop, used
with permission.
The quantification of infectivity of different viruses in single cycle reporter assays
can be further refined by mixing viruses with different reporter genomes together and
using the mixture to infect cells. This allows for a comparison of two viruses in precisely
the same infection and effectively eliminates variables inherent in assays utilizing parallel
cell cultures. In these experiments mixtures of gGag+ and gGag- virus stocks carrying
distinct retroviral reporter genes were adjusted to give equal focus forming units (FFUs)
and used to simultaneously assess both viruses in the same infection on 3T3 cells or
3T3/mA3 cells. The results of these experiments corroborated the earlier findings
regarding inhibition by cellular mA3 and are described in Chapter 3.
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2.4 Determination of virion-specific infectivity
Many studies have shown that hA3g is incorporated into HIV-1 ΔVif
virions23,100,126,128,141,173,179,182. Some studies have also shown that mA3 is incorporated
into the virions of MuLVs100,100,188,188,203,203. Incorporated A3 proteins affect the
infectivity of the virions on target cells irrespective of whether they express mA3 or
not23,100,126,128,141,173,179,182. Inhibition of infectivity by virion-associated mA3 would be
reflected in a decrease in the specific infectivity of the virions. In order to measure the
affect of virion-associated mA3 on MuLV infectivity, virions were produced from mA3
expressing cells as well as from cells not expressing mA3 and normalized to the number
of virion particles by the quantification of reverse transcriptase (RT) activity. This has
been done in other studies100,123,192,204 using the enzymatic activity of the virion RT. It is
possible, however that the presence of mA3 in the virion may affect the RT activity
rendering it an unreliable measure of virion quantity. For this reason, the level of the
major structural protein, p30, was estimated through immunoblotting procedures to
provide an independent measure. In all of the virus stocks generated in these studies, the
RT activity reflected the level of p30.
The virions used for these studies were produced from mA3 expressing cells
transduced with the LAPSN reporter genome and subsequently infected with the gGag+
or gGag- virus. Stocks collected from these cells consist of virions that have packaged
the reporter LAPSN genome or alternatively, the MuLV genome, enabling the assay of
released viruses by either the reporter assay or the FIA. Released virions were assayed
for infectivity on Mus dunni cells. The choice of Mus dunni cells was based on their
permissiveness to infection with high efficiency by MuLVs.
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In these experiments, the

titers of the viruses measured by the FIA were similar to titers measured by the alkaline
phosphatase assay and the data from the two assays were combined. These experiments,
described in chapter 3, indicated that virion-associated mA3 affected MuLV specific
infectivity in a gGag-dependent manner.
2.5 Determination of in vivo replication
Both cellular and virion-associated mA3 were shown to restrict infectivity of
MuLVs in a gGag-dependent manner101. It was unknown, however, if mA3 exerted a
similar effect in vivo. In order to determine if there was a gGag-dependent effect of mA3
on MuLV replication in vivo, knock-out mouse strains in which the mA3 gene had been
inactivated (mA3-/-) and their wild-type counterparts (mA3+/+) were utilized164. Two
mouse strains were examined in these studies. The 129/Ola strain predominately
expresses the full-length mA3164 similar to the isoform utilized in the in vitro studies
while the C57BL/6 strain predominantly expresses the delta exon 5 splice variant164. The
C57BL/6 strains were included in the study because of the ease with which mouse
colonies could be maintained compared to the 129/Ola strains. Furthermore, analyses in
C57BL/6 mice provide an assessment of the in vivo activity of a distinct mA3 isoform.
The absence of an antibody specifically reactive with mA3 makes the assessment
of in vivo levels of the protein difficult.

mRNA measurements suggest that the

expression of the protein increases during development and that mA3 expression is
largely tissue-specific159,164.

With these considerations, the assessment of MuLV

replication was accomplished at various times after infection by measuring viremia in the
mice. Viremia was measured with the expectation that it would more closely reflect total
virus production in the animal than assays of particular tissues. Viremia data for the
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knock out and wild-type mouse strains supporting an in vivo effect of gGag on the action
of mA3 is presented in Chapter 3.
2.6 Protein analysis of infected cells and virions
To determine expression of mA3 and viral proteins in the cell and virions,
immunoblots of proteins resolved by electrophoresis on polyacrylamide gels (PAGE)
were utilized. The rabbit gGag-antibody was initially provided in the form of antiserum63.
Use of the antiserum presented background problems in the immunoblot procedure that
was not corrected by increased incubation times in blocking reagents or by extensive
washing. Further, the antiserum reacted poorly with HRP conjugated anti-rabbit
antibodies tested. In attempts to alleviate these problems, IgG from the antiserum was
purified using protein G and the IgG fraction directly conjugated with HRP. This
procedure coupled with the addition of 5% rabbit serum to the standard blocking buffer
markedly reduced the background seen with the anti-gGag antiserum. Other antibodies
used in these studies were also directly conjugated to HRP, which significantly reduced
background.
Immunoprecipitation of mA3 and viral proteins from lysates of cells or virions for
immunoblot analysis was achieved with purified, unconjugated antibodies. In order to
eliminate non-specific absorption of proteins to the protein G Dynal beads used in the
immunoprecipitation experiments, beads were first bound to the antibody under
saturating conditions. The bead/antibody complexes were then incubated in the presence
of 10% BSA to minimize non-specific protein binding. In addition, the lysates were preabsorbed with unconjugated protein G Dynal beads to reduce the level of non-specific
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binding proteins. Immunoprecipitated complexes subjected to PAGE were analyzed by
immunoblot procedures.
The localization of mA3 and gGag in infected cells was determined by confocal
microscopy. During the course of these analyses it was found that sequential incubation
of antibodies specific for HA-mA3 (rat) and gGag (rabbit) with the cells rather than
incubation with a mixture of the antibodies yielded far superior images. These primary
antibodies were then detected by fluorescent goat anti-rat or anti-rabbit antibodies. These
analyses are presented in chapter 4.
2.7 Localization of virion-incorporated mA3 and gGag
For determination of the localization of mA3 and gGag in the virion, virions
purified by isopycnic centrifugation54 on sucrose gradients were applied to a 10-30%
sucrose step gradient, with the 10% layer containing detergent to separate the outer
membrane of the virion from the virion core. This procedure was adapted from
previously reported methods to differentiate membrane components from the core
components

of

various

retroviruses3,136,140,162.

retroviruses

including

human,

avian

and

murine

The level of detergent was adjusted to eliminate the outer

envelope protein from the sedimented core. It is important to note that these conditions
also resulted in the loss of substantial levels of the major structural core protein, in
agreement with previously reported studies3,136,140,162. These experiments revealed the
presence of both gGag and mA3 in the virion core and are presented in chapter 4.
2.8 Determination of G-to-A hypermutation
mA3 and hA3G both exhibit cytidine deaminase activity at the level of the single
stranded transcripts produced during reverse transcription. This process which results in
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G-to-A mutations is thought to be a primary mechanism for retrovirus restriction4,12,13. It
was of interest to determine if this mechanism is operative in the restriction of MuLVs
and if it is affected by the presence of gGag. To determine the rate of G-to-A mutation in
the presence of cellular mA3, cells expressing or not expressing mA3 were infected with
either the gGag+ or gGag- MuLV. A 24 hour time point after infection was chosen to
avoid additional replicative cycles which would complicate the mutational analyses.
After 24 hours, total DNA was harvested from the cell and the proviral DNA was
amplified by PCR, cloned and sequenced to detect point mutations.

A similar

methodology was used to determine the effects of virion-associated mA3. In these
determinations, virions produced from cells expressing or not expressing mA3 were used
to infect Mus dunni cells. It is known that cells have evolved mechanisms to degrade
uracil-containing DNA18. It is possible that mutated transcripts might be eliminated by
such a mechanism, yielding an underestimate of the actual incidence of mutations. This
possibility was addressed by determining the mutations in transcripts produced by viruses
isolated from cells expressing or not expressing mA3. Transcripts were produced in cellfree RT reactions with lysed virions, amplified by PCR, cloned and sequenced. This
procedure eliminated any possible effect of transcript elimination by cellular machinery;
however, the analysis was limited to the action of virion-associated mA3. In contrast to
many

other

reported

studies,

the

viral

genome,

rather

than

an

artificial

transcript18,99,110,145, was used to determine the mutation rate. To make sequence analysis
comparable among all experiments, sequences of the PCR amplicons were trimmed to
755 bp to minimize ambiguous sequence data and to ensure uniformity. Although steps,
such as biological cloning of the viruses, were taken to minimize pre-existing sequence
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heterogeneity this is difficult to achieve with retroviruses due to the unedited replication
of RNA viral genomes, Furthermore, amplification of a limited number of proviral
transcripts could result in multiple clones of the same transcript which would contain the
same mutations. The probability of a base change occurring randomly in multiple clones
at the same position is quite small. Therefore, only those mutations found to be unique
were considered in these analyses. Mutation rates were calculated as the number of
mutations per nucleotide sequenced and are presented in chapter 4.
2.9 Determination of transcript levels
While deamination seems to be the main mechanism of action used by APOBEC3
proteins to inhibit retroviral replication, other mechanisms have been observed. In HIV
infection, cellular hA3G was shown to inhibit replication by inhibiting the initiation of
reverse transcription29.

Similarly, no deamination activity was observed following

infection by M-MuLV, however, the small inhibition of replication associated with mA3
was attributed to a reduction of viral transcripts in the cell18. As described in chapter 4,
there was no significant difference in cytidine deaminase activity in the presence or
absence of mA3 or gGag. It is possible that mA3 affects viral replication by restricting
the level of proviral synthesis in infected cells in a gGag-dependent manner. To examine
this possibility viral transcript levels in cells infected by either gGag+ or gGag- MuLVs
were quantified at 8 and 24 hours after infection by PCR. Primers were employed that
would specifically amplify the infecting viral sequences rather than endogenous retroviral
sequences present in the mouse genome. The results of these analyses indicate a gGagdependent reduction in viral transcript levels in the contexts of both cellular and virionassociated mA3, and are described in chapter 4.
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Chapter 3- The glycosylated Gag protein of a murine leukemia virus inhibits the
anti-retroviral function of APOBEC3
3.1 Abstract
APOBEC proteins have evolved in both humans and mice as innate defenses
against retroviral infections. To counteract the effects of human APOBEC3G, HIV has
evolved the Vif protein. Murine leukemia viruses (MuLVs) that infect and replicate in
mice do not encode a Vif homologue and it has not been understood how they evade
mouse APOBEC3 (mA3). We report here a MuLV that utilizes a glycosylated form of its
gag protein (gGag) to counteract mA3. gGag is critical for infection of mA3-expressing
cell lines and for the infectivity of released viruses which have encapsulated mA3.
Finally, a gGag-deficient virus that is restricted for replication in wild-type mice
replicates efficiently in mA3 knockout mice implying a novel role of gGag in
circumventing the action of mA3 in vivo.

Studies described in this chapter were published in Virology:
Kolokithas, A., K. Rosenke, F. Malik, D. Hendrick, L. Swanson, M. L. Santiago, J.
L. Portis, K. J. Hasenkrug, and L. H. Evans. 2010. The glycosylated Gag
protein of a murine leukemia virus inhibits the antiretroviral function of
APOBEC3. J Virol 84:10933-10936.
3.2 Introduction
APOBEC3G (hA3G) in humans and its mouse ortholog, APOBEC3 (mA3), act as
potent innate defenses against retroviral infection. Both proteins deaminate cytidine in
single-stranded DNA ultimately resulting in hypermutation of newly synthesized proviral
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DNA28,110, although additional deaminase-independent mechanisms of inhibition have
been identified4. Infectious exogenous retroviruses, including HIV and murine leukemia
viruses (MuLVs), have evolved mechanisms to circumvent the action of the APOBEC
proteins12,28. HIV encodes the Vif protein which facilitates the rapid proteolysis of
hA3G, while the mechanism by which exogenous MuLVs evade the action of mA3 is
unknown28.
Exogenous MuLVs, as well as some other gamma retroviruses, encode a
glycosylated gag protein (gGag) originating from an alternate translation start site
upstream of the methionine start site of the gag structural polyproteins54,112,154. gGag is
synthesized at similar rates and levels as the structural gag polyprotein in MuLV infected
cells but is glycosylated and undergoes distinct proteolytic processing65,133. A carboxyl
fragment of gGag is released from the cell while an amino fragment is incorporated into
the plasma membrane as a type 2 transmembrane protein65,147. The functions of gGag
remain unclear, but mutations that eliminate its synthesis severely impede in vivo
replication of the virus with little, if any, effect on replication in fibroblastic cell
lines36,121,153.

APOBEC3 proteins are expressed in many tissues in vivo but are poorly

expressed in many in vitro cell lines28 suggesting a possible link between gGag
expression and the evasion of mA3 by MuLVs. These studies were undertaken to
determine if the expression of the gGag protein facilitated MuLV replication in the
presence of mA3 in vitro and in vivo.
3.3 Materials and methods
3.3.1 Plasmids, cells and viruses.

The plasmid encoding the full length mA3

derived from the BALB/c mouse strain was a kind gift from Dan Littman18. It was
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provided in the pcDNA3 vector and was tagged at the C-termini with hemagglutinin
(HA)18. NIH3T3 (3T3) and Mus dunni cells were maintained in Dulbecco‟s modified
Eagle medium with 10% bovine serum and penicillin/streptomycin. Quantitative RT
PCR assays using the forward primer (ACCTGAGCCTGGACATCTTCA), the reverse
primer

(TGCAAAGATTCTGCTGGTTTTC)

and

the

FAM-TAMRA

probe

(TCCCGCCTCTACAACATACGGGACC) revealed that mA3 RNA was below the level
of detection in both 3T3 and Mus dunni cells (data not shown). Plasmid DNA was
transfected into 3T3 or Mus dunni cells using lipofectamine (Life Technologies)
according to the manufacturer‟s instructions and selected in media containing 1 mg/ml
G418. Single colonies of cells were transferred to new dishes and tested for their ability
to stably express the C-terminal HA-tagged mA3 construct after ten passages. 3T3 and
Mus dunni cells stably expressing the C-Terminal HA-tagged mA3 construct (3T3/mA3
and Mus dunni/mA3 cells, respectively) were maintained in selection media. CasFr KP
(gGag+) is an MuLV derived from the wild mouse ecotropic virus CasBrE and contains a
short sequence of the F-MuLV, FB29, which includes the initiation site of the gGag
protein

152

. CasFr--3+4 (gGag-) is a derivative of CasFrKP in which mutations have been

introduced to disrupt the expression of gGag153. Mice were infected by intraperitoneal
injection with approximately 2 x 105 infectious units of virus within hours of birth.
3.3.2 Virus isolation. Virus was harvested from 3T3/mA3 cells infected with
either gGag+ or gGag- viruses and purified by isopycnic gradient centrifugation as
previously described54.

Briefly, supernatants were collected from infected cells and

cleared of cellular debris by low speed centrifugation. Cleared supernatants were
subjected to ultracentrifugation to pellet the virions. Pellets were resuspended in buffer
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and placed on a 20 to 60% linear sucrose gradient for further ultracentrifugation. The
fraction of the gradient containing virions was pelleted by ultracentrifugation,
resuspended in a storage buffer and kept at -20C until used in further experimentation.
3.3.3 Mice. The derivation of 129P2/OlaHsd mA3-/- and C57BL/6 mA3-/- mice
has been previously described164. C57BL/6 and 129P2/OlaHsd mice were obtained from
Jackson Laboratories and Harlan Laboratories, respectively. In the interest of brevity,
129P2/OlaHsd will be referred to as 129/Ola mice throughout this article. Mice were
treated in accordance with the regulations and guidelines of the Animal Care and Use
Committee of the National Institutes of Health.
3.3.4 Assays of viral infectivity. The quantification of viruses in single cycle
infectivity assays was accomplished using the retroviral vectors LAPSN (Clontech
Laboratories, Inc.) and G1nβgSVNa92. Briefly, cells were plated in 60 mm tissue culture
dishes, the cells infected the next day with virus and allowed to grow to confluence (3-4
days). Foci of cells expressing alkaline phosphatase or β-galactosidase were detected as
previously described92 and counted as focus-forming units (FFU).

For mixed virus

assays, vectors pseudotyped within gGag+ or gGag- virions were harvested from 3T3
cells that had been transduced with LAPSN or G1nβgSVNa.

Mixtures of gGag+ and

gGag- virus stocks carrying distinct retroviral vectors were adjusted to give equal FFUs
and used to simultaneously assess both viruses in the same infection on 3T3 cells or
3T3/mA3 cells. For assays of progeny viruses released from 3T3 cells or 3T3/mA3 cells,
the cell lines were transduced with the LAPSN vector and subsequently infected with a
gGag+ or gGag- MuLV. The levels of progeny virus were assessed on Mus dunni cells
and were normalized for reverse transcriptase activity using a colormetric reverse
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transcriptase kit (Roche) according to the manufacturer‟s instructions. Reverse
transcriptase activity was expressed as the absorbance at 405nm per ml. The infectivity
of progeny virus released from 3T3 or 3T3/mA3 cells was also quantified using a
monoclonal antibody (mAb) specifically reactive to the envelope protein of the viruses,
mAb 667127, in focal immunofluorescence assays175.
3.3.5 Immunoblotting.

After virus isolation, samples were lysed in Protein

Extraction reagent Type 4 (Sigma) and incubated for 10 minutes at room temperature.
For cell lysate samples, monolayers were lysed by addition of lysis buffer (0.01M
NaH2PO4 [pH 7.6], 0.001M EDTA, 1% Triton X-100, 0.1 % SDS). Cell lysates harvested
from the plates were centrifuged at 13,000 x g for 10 minutes to separate the soluble and
insoluble fractions. The soluble protein fraction was used to measure total protein
concentration in the sample using a Bradford assay (Pierce) according to the
manufacturer‟s protocol. Samples were normalized according to their protein
concentrations and were adjusted to 1X Laemmli sample buffer containing 5% βmercaptoethanol and boiled for 10 minutes. The samples were then subjected to SDSPAGE (10% acrylamide, Life Technologies), followed by transfer onto PVDF
membranes. Western Blot analysis was performed by probing with monoclonal anti-HA
horseradish peroxidase (HRP)-conjugated antibody (Roche), polyclonal rabbit anti-gGag
HRP-conjugated antibody or an HRP-conjugated monoclonal anti-p30 antibody (mAb
18-7)25.

Membranes were stripped using 62.5 mM Tris-HCl, pH 6.8, 100 mM β-

mercaptoethanol, 2% SDS for 30 minutes at 55o C on a rotary shaker. The anti-gGag
antibody and the monoclonal anti-p30 antibody were purified using a HiTrap protein G
HP affinity column (GE Healthcare) according to the manufacturer‟s instructions.
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Antibodies were conjugated to HRP using a Lightning-Link HRP conjugation kit (Innova
Biosciences) according to the manufacturer‟s instructions.
3.4 Results
3.4.1 Efficient infection of mA3-expressing cells is dependent on gGag.
Several reports of the effects of mA3 proteins on virus replication have examined the
infectivity of virions released from cells transfected with cloned proviral DNA in the
presence or absence of mA351,110,162. Such analyses do not test effects of mA3 present in
the cytoplasm of the cells on the infectivity of MuLVs that have not been previously
exposed to mA3. To address this issue we developed a 3T3 cell line that expressed an
HA-tagged mA3 protein (3T3/mA3). The infectivity of the gGag+ and gGag- MuLVs
was compared on 3T3 and 3T3/mA3 cells using mixtures of the viruses, each carrying a
distinct retroviral vector encoding either alkaline phosphatase (LAPSN) or Bgalactosidase (G1nBgSvNa). Utilizing mixtures of viruses with different readouts

Figure 3.1. Effect of cellular mA3 on infection by gGag+ or gGag- MuLVs.
3T3 and 3T3/mA3 cells were infected with mixtures of gGag+ and gGag- viruses, each
carrying a distinct retroviral vector encoding either alkaline phosphatase (LAPSN) or βgalactosidase (G1nβgSvNa) and assayed by scoring FFU of cells expressing the
respective enzymes. The mixtures were adjusted to give equivalent titers of alkaline
phosphatase and β-galactosidase on 3T3 cells. Statistical analysis was performed using
the unpaired Student's t test.
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for infectivity enabled the assessment of the effects of cellular mA3 on both viruses in
precisely the same infection.
Experiments were performed using both MuLV/vector combinations (i.e.,
LAPSN(gGag+

MuLV)

plus

G1nβgSvNa(gGag-

MuLV)

or

alternatively,

G1nβgSvNa(gGag+ MuLV) plus LAPSN(gGag- MuLV)). These analyses indicated that
cellular mA3 exerted a marked inhibitory effect on the infectivity of gGag- virus but not
on the gGag+ virus (Figure 3.1).
3.4.2 Both gGag+ and gGag- MuLVs incorporate mA3 into progeny virions. A
number of studies have reported partial inhibition of ecotropic MuLVs as a result of
incorporation of mA3 into progeny virions110,123,162,188. Indeed, it has been suggested that
MuLVs may evade the action of mA3 by exclusion of the protein from virions, although
there are conflicting accounts regarding this matter18,43,100,110,145,162. To determine if the
presence of gGag influenced the incorporation of mA3, virions were isolated from mA3
cells infected with gGag+ or gGag- MuLVs and examined by immunoblot analyses. mA3
was readily detected in both virus preparations with no discernible differences in the
levels of virion incorporation in gGag+ or gGag- MuLVs (Figure 3. 2A). This result is in
agreement with other reports that have shown incorporation of mA3 into virions
18,100,145,162

. Furthermore, gGag was also found to be incorporated into virions (Figure

3.2B) consistent with an earlier study63.
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Figure 3.2. Infectivity of virions released from 3T3 or 3T3/mA3 cells infected with
gGag+ or gGag- MuLVs.
Virions released from 3T3/mA3 cells infected with gGag+ or with gGag- were analyzed
by immunoblotting for the presence of mA3 or gGag. A). Immunoblot analysis of
gGag+ virions, gGag- virions and a 3T3/mA3 cellular lysate for the presence of mA3
using a HRP-conjugated anti HA antibody. The 3T3/mA3 cellular lysate was included
as a comparison of mA3 in the cells to that in the virions. The blot was also developed
with a HRP-conjugated monoclonal antibody to p30 as a loading control. Exposure
times for detecting mA3 were approximately 10-fold longer than for p30.
B).
Immunoblot analysis of gGag+ or gGag- for the presence of gGag using a HRPconjugated anti gGag antibody. The blot was subsequently stripped and developed
with an HRP-conjugated monoclonal antibody to p30 as a loading control. Exposure
times for detection of gGag were approximately 20-fold longer than for p30. C). 3T3
cells or 3T3/mA3 cells harboring the retroviral vector LAPSN were infected with
gGag+ or gGag- MuLVs. Infectivity of progeny virions was assessed on uninfected M.
dunni cells by alkaline phosphatase assays and by FIA. Infectivity titers, expressed as
FFUs were normalized to the number of virions by assessing reverse transcriptase
activity (RT). RT was expressed as the absorbance per ml at 405nm. Statistical
analysis was performed using the unpaired Student's t test.
3.4.3 Virion-associated mA3 selectively inhibits gGag- MuLV infectivity. To
determine if virion-incorporated mA3 differentially influenced gGag+ and gGag- MuLVs
we examined the infectivity of viruses released from 3T3/mA3 cells as well as from 3T3
cells lacking mA3. Both cell lines were transduced with the retroviral vector, LAPSN,
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which encodes alkaline phosphatase to enable the quantification of progeny virus
infectivity in single cycle assays. Cells were infected with gGag+ or gGag- MuLVs and
released viruses were quantified in assays on Mus dunni cells. Infectivity was normalized
to the relative number of virus particles by quantifying reverse transcriptase activity.
Considering that the reverse transcriptase activity included virions carrying the retroviral
vector as well as virions carrying the MuLV genome, the infectivity of progeny virus
released from 3T3 or 3T3/mA3 cells was also quantified using a monoclonal antibody
specifically reactive to the envelope protein of the viruses in focal immunofluorescence
assays. The retroviral vector assays and the fluorescence assays closely paralleled one
another and the results were combined (Figure 3.2C). These analyses revealed that the
infectivity of gGag- virus released from 3T3/mA3 cells was markedly decreased
compared to gGag- virus released from 3T3 cells. In contrast, no significant differences
were observed in the infectivity of gGag+ virus released from 3T3/mA3 and 3T3 cells
(Figure 3.2C). Experiments using a Mus dunni cell line expressing the mA3 protein to
assess the effects of cellular as well as virion-incorporated mA3 on the infectivity of
gGag+ and gGag- MuLVs yielded similar results (data not shown).
3.4.4 mA3-deficient mice support the replication of gGag+ and gGag- MuLVs.
If mA3 restriction is a major factor influencing in vivo replication of MuLVs and its
action is sufficiently repressed by gGag, it would be expected that mice lacking mA3
would be permissive to infection by both gGag+ and gGag- MuLVs.

To examine this

possibility we determined the level of replication of gGag+ and gGag- MuLVs in mA3
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Figure 3.3. Replication of gGag+ or gGag- MuLVs in wild type and mA3 knockout
mice.
A). 129/Ola wild type (mA3+/+) or 129/Ola mA3 knockout (mA3 -/-) mice were inoculated
with gGag+ or gGag- MuLVs. Three weeks after infection the mice were sacrificed, sera
collected and viruses quantified by a focal immunofluorescence assay on M. dunni cells.
n=9 for gGag+ MuLV in mA3+/+ mice, n=9 for gGag+ MuLV in mA3-/-mice, n=7 for gGagMuLV in mA3+/+ mice and n=14 for gGag- MuLV in mA3-/- mice. Statistical analysis was
performed using the unpaired Student's t test. B). C57BL/6 wild type mice (mA3+/+) or
C57BL/6 mA3 knockout mice (mA3-/-) were inoculated with gGag+ or gGag- MuLVs.
Three weeks after infection the mice were sacrificed, sera collected and viruses quantified
by focal immunofluorescence assays on M. dunni cells. Each point represents the level of
viremia from an individual animal with n=6 for the gGag+ MuLV in mA3+/+ mice, n=7 for
the gGag+ MuLV in mA3-/- mice, n=9 for the gGag- MuLV in mA3 +/+ mice and n=11 for
the gGag- MuLV in mA3-/- mice. Wilcoxon Signed rank test was used to differentiate
whole number integers from zero values. The unpaired Student‟s t test was used to
compare non-zero results.
knockout mice (mA3-/-) and their wild type counterparts (mA3+/+). Comparisons of the
replication of gGag+ and gGag- MuLVs revealed a clear influence of 129/Ola mA3 on
their replication (Figure 3.3A). In agreement with previous studies on the replication of
gGag-deficient mutants36,123,153, the replication of the gGag- MuLV was severely
restricted in normal 129/Ola mice. However, in 129/Ola mice lacking mA3, the gGag+
and gGag- MuLVs replicated to equally high levels. These results indicate that the
inability of the gGag- MuLV to replicate efficiently in vivo is the result of mA3
expression.
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C57BL/6 mice contain the Fv1b allele181. The MuLVs used in this study are Ntropic, thus the levels of replication of the MuLVs in C57BL/6 mice were much lower
than in the 129/Ola mice, which contain the Fv1n allele (Figure 3.3B)181. Nevertheless,
replication in these mice was sufficient to observe mA3 inhibition in a gGag-dependent
manner. Replication of the gGag+ MuLV was easily detectable in both C57BL/6 mA3+/+
and mA3-/- mice, while replication of the gGag- MuLV was below the level of detection
in the wild-type C57BL/6 mA3+/+ mice. However, in C57BL/6 mA3-/- mice, the gGagMuLV replicated to the same level as the gGag+ MuLV. Thus, the inability of the gGagMuLV to replicate in vivo in C57BL/6 mice is the result of mA3 expression, similar to
our findings using 129/Ola mice. It is noteworthy that C57BL/6 mice predominantly
express a splice variant mA3 mRNA which lacks exon 5 while 129/Ola mice
predominantly express a complete mA3 mRNA.

Assuming that the mRNAs are

translated with equal efficiencies, our results indicate that the MuLV gGag studied here is
able to suppress the antiviral effect of both the full-length and exon 5-deleted proteins.
3.5 Discussion
Nearly all exogenous MuLVs contain sequences encoding gGag which is
synthesized from an alternate initiation site upstream of the start site of the gag
polyprotein48,154.

Although studies have found gGag to be necessary for in vivo

replication, the basis for this effect was unknown36,121,153. Moreover, the means by which
exogenous MuLVs evade the action of mA3 was unclear28,162. Our results establish a
novel role of gGag as an antagonist of mA3 thereby providing insight into both of these
questions.
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We observed gGag-dependent inhibition by mA3 in two distinct contexts:
inhibition of infectivity by mA3 expressed in the cell as well as inhibition by virionassociated mA3. Interestingly, it was recently reported that infection by Moloney MuLV
(M-MuLV) was partially inhibited by mA3 and that both virion and cellular mA3
contribute to the inhibition123. Inhibition of infection by both virion and cellular mA3 has
also been observed with mouse mammary tumor virus138. Furthermore, HIV has also
been reported to be inhibited by cytoplasmic hA3G196.
It is somewhat surprising that cellular mA3 exerts a gGag-dependent effect on
infecting MuLVs. The level of gGag incorporated into virions is low compared to the
structural proteins but clearly detectable. Furthermore a previous study of the gGag+
MuLV utilized here indicated that gGag is indeed a component of the virion63. Virionassociated gGag may directly influence the action of cellular mA3. Alternatively, the
susceptibility of the gGag- MuLV to cellular mA3 may occur by an indirect mechanism.
In this regard, it has been reported that gGag is involved in virion release and that gGagM-MuLV exhibits an abnormal morphology during virion budding121. It is conceivable
that mature virions may also be altered from an mA3-resistant to an mA3-susceptible
phenotype.
We observed that progeny virions released from mA3 expressing cells were also
inhibited in a gGag-dependent manner. While the level of gGag incorporated into virions
is low, in infected cells the rate of synthesis and the level of gGag are comparable to that
of the unglycosylated Gag polyprotein precursor54. It is possible that gGag counteracts
the action of mA3 on progeny virions by a mechanism distinct from the effect of virionassociated gGag on cellular mA3 discussed above. Although both gGag+ and gGag-
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MuLVs incorporate mA3 into virions at similar levels we have not determined if this
incorporation is qualitatively the same with both MuLVs. It is possible that the virionassociated mA3 is altered in its location or association with virion components in the
gGag+ MuLV. Such an alteration could be influenced by an interaction of the newly
synthesized gGag with mA3 in the cell. The mechanism(s) by which gGag influences the
action of mA3 awaits further investigation.
A very recent report indicates that gGag exhibits some functional similarities to
the Nef protein of HIV149. Nef is an accessory protein of HIV and SIV that exhibits an
incredibly complex range of functions that include down regulation of CD4 and MHC
proteins67,169,
transcription168.

induction

of

apoptosis68

and

increasing

efficiency

of

reverse

Nef is incorporated into virions facilitating infectivity and in vivo

replication19,94,95,144, however an influence of Nef on the action of APOBEC3 proteins has
not been described. It is quite possible that gGag, like Nef, has more than one function in
the virus life cycle.
Our analyses indicated that mA3 did not inhibit the gGag+ MuLV, however a
number of studies have reported partial to marked inhibition of other MuLVs110,123,162,188,
all of which encode a gGag protein. A direct comparison of the inhibitory effects of mA3
on M-MuLV and the ecotropic AKV MuLV revealed that AKV was inhibited to a greater
extent than M-MuLV110.

Furthermore, inhibition of M-MuLV by mA3 was not

accompanied by G-to-A mutations in newly synthesized DNA110,162, whereas inhibition
of AKV by mA3 exhibited extensive G-to-A mutations110.

Differences in the

susceptibility of MuLVs to inhibition by mA3 could reflect differences in the efficacy of
their respective gGags to counteract mA3. In this regard, a comparison of the gGag
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sequences of M-MuLV and AKV reveals extensive amino acid differences in their aminoterminal fragments (data not shown).
A xenotropic murine leukemia–like retrovirus (XMRV) has been found in human
prostate cancer tissue as well as in cohorts of patients diagnosed with chronic fatigue
syndrome

59,120,166,193

. Recent studies have reported that mA3 inhibits the replication of

XMRV to a much greater extent than M-MuLV74,145. It is noteworthy that all XMRV
isolates exhibit a termination codon in the coding sequences of gGag resulting in a
truncation of the protein just before the transmembrane region193. Thus, the sensitivity of
XMRV replication to mA3 may reflect the absence of a functional gGag.
In agreement with earlier studies, we observed a marked inhibition of in vivo
replication of the gGag- MuLV compared to the gGag+ MuLV. Levels of the gGagMuLV were restored to the high levels observed with the gGag+ MuLV in 129/Ola KO
mice lacking mA3. These results further substantiated the role of gGag as an antagonist
of the restriction factor. Similar results were observed with C57BL/6 mice with the level
of replication of the gGag- MuLV reaching levels observed for the gGag+ MuLV in mA3-/mice. The level of replication of the gGag+ MuLV in C57BL/6 mA3+/+ mice was low due
to Fv1 restriction and was not significantly increased in C57BL/6 mA3-/- mice. This
result differs from studies of M-MuLV replication in C57BL/6 mA3-/- mice indicating
enhanced MuLV replication compared to replication in C57BL/6 mA3+/+ mice123. In
contrast to M-MuLV, which is moderately inhibited by mA3110,123,162, the gGag+ MuLV
utilized in this study was not inhibited. This difference would account for the increased
replication of M-MuLV in the absence of mA3.
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These studies provide at least partial answers to two difficult questions in
retrovirology: those of the function of the gGag of MuLVs and the means by which
MuLVs evade the action of APOBEC3. Although the gGag of exogenous MuLVs
provides a similar function as the Vif protein of HIV, further studies are required to
determine similarities and differences in their mode of action.

Such studies are

particularly relevant in light of recent reports indicating cross-species retroviral infections
from mouse to humans120,166,193.
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Chapter 4-The Murine leukemia virus gGag protein facilitates reverse transcription
in the presence of murine APOBEC3
4.1 Abstract
Humans and mice have evolved APOBEC proteins that act as innate defenses
against retroviral infections. We have recently reported that a MuLV utilizes a
glycosylated form of its Gag protein (gGag) to effectively inhibit the antiviral activity of
murine APOBEC3 (mA3) in vitro. Our results indicated that gGag-dependent inhibition
by mA3 occurs in two different contexts: cellular mA3, which inhibits initial infection of
the cell by MuLVs not previously exposed to mA3; and virion-associated mA3, present in
progeny MuLVs released from cells expressing mA3. Infection by MuLVs containing
mA3 is inhibited irrespective of the expression of mA3 in the target cells.

The

mechanism by which gGag is protective against mA3 is unknown. To counteract the
human APOBEC3G (hA3g), HIV has evolved the Vif protein, which depletes hA3g from
infected cells by facilitating its degradation through the proteosome. We report here that a
gGag-containing MuLV does not deplete mA3 from an infected cell. Further,
immunoprecipitation and localization experiments suggest that mA3 does not interact
with gGag directly in an infected cell. In contrast, both gGag and mA3 are associated
with the virion core and are coprecipitated in the context of the mature virions. Both
hA3g and mA3 have been reported to use deamination-dependent and -independent
mechanisms to inhibit retroviral replication. Inhibition by mA3 on gGag-deficient virions
correlates with a decrease in the level of transcripts upon infection of cells and appears
largely independent of deamination activity.
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4.2 Introduction
APOBEC3s (hA3G in humans, mA3 in mice) are cytidine deaminases that act on
single-stranded DNA during reverse transcription resulting in hypermutation of newly
synthesized proviral DNA28,110. HIV-1 has a gene product, Vif, to counteract hA3G
antiviral effects. Vif binds to the N-terminal of hA3G and recruits a ubiquitin ligase
complex that marks hA3G for destruction in the proteasome34. Vif has also been shown to
impair the translation of hA3G mRNA128 and prevent encapsulation by binding to
hA3G141. MuLVs are largely insensitive13 to the actions of murine APOBEC3 (mA3),
although this has recently become a point of controversy18,43,100,110,145,162. It appears that
MuLVs escape mA3 activity without a Vif-like accessory protein.
APOBEC3 family members from both humans and mice inhibit endogenous LTR
retrotransposons and retroviruses12,49,50. A major difference between exogenous and most
endogenous MuLVs in the mouse is the absence of a sequence for the expression of
gGag. The gGag protein is translated from the same viral mRNA as Gag, but uses a CUG
start codon that is upstream of the AUG start codon for Gag54,65,133 resulting in an
additional 88 amino acids on the N-terminus of Gag. The protein is then targeted to the
rough endoplasmic reticulum for glycosylation and is subsequently exported to the cell
surface65,147 where it is cleaved in the CA domain. Some of the C-terminal portion of
gGag is secreted whereas some of the N-terminal portion adopts a type II integral
membrane configuration65,147. The amounts of Gag and gGag synthesized in infected cells
are similar, however the amount of gGag incorporated into the virion is low compared to
other Gag structural proteins65. MuLVs require gGag for efficient replication in vivo and
it is a major determinant of virulence

65

. However, gGag is not required for efficient in
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vitro replication, as the mutant viruses that lack gGag are able to replicate in cell lines
with similar efficiency to their wild-type counterparts63,65,121. In a recent report we
observed that mA3 suppresses the replication of a gGag- virus compared to a gGag+ virus
both in vitro and in vivo, however the mechanism by which gGag exerts this effect is
unclear. The present studies were undertaken to investigate possible mechanisms by
which gGag evade the action of mA3.
4.3 Materials and Methods
4.3.1 Plasmids, cells and viruses. The maintenance of cell lines, the derivation
of cells expressing mA3 by transfection of plasmids and the use of viruses in this study
were as described in chapter 3.3.1.
4.3.2 Virion core isolation. Total virion isolation is described in chapter 3.3.2.
For isolation of viral cores, a suspension of purified virions was sedimented through a 1030% sucrose step gradient in PBS containing 5% IGEPAL, in the 10% sucrose layer of
the gradient. The gradients were centrifuged at 30,000 rpm for 1.5 hours after which the
pellets were resuspended in Laemmli sample buffer containing 5% β-mercaptoethanol
and samples were incubated in a boiling water bath for 10 minutes.
4.3.3 Immunoblotting. Immunoblotting procedures were performed as described
in chapter 3.3.5.
4.3.4 Determination of cellular mA3 levels. The effect of infection on the levels
of cellular mA3 was examined in 3T3/mA3 cells infected with either gGag+ or gGagMuLVs. Forty-eight hours after infection, cells were harvested and analyzed by
immunoblot analysis. The level of mA3 was normalized by comparing its signal intensity
to GAPDH or b-Actin signal intensity using ImageQuant software (GE).
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4.3.5 Immunoprecipitation. Purified virions were lysed in 50 mM Tris, 80 mM
potassium chloride, 0.75 mM EDTA and 0.5% Triton X-100, pH 7.8, and incubated for
30 minutes at room temperature. Confluent monolayers of cells were lysed by addition
of Cell lytic M cell lysis reagent (Sigma). Cell lysates harvested from the plates were
centrifuged at 13,000 x g for 10 minutes to separate the soluble and insoluble fractions.
The total protein concentration in the soluble fraction was determined using a BCA assay
(Pierce) according to the manufacturer‟s protocol. Samples were normalized according to
their protein concentrations. Protein G Dynal beads (Invitrogen) were incubated in the
presence of monoclonal anti-HA antibody (Roche), polyclonal rabbit anti-gGag antibody
or a monoclonal anti-p30 antibody (mAb 18-7). The bead/antibody mixtures were then
incubated with BSA to block non-specific binding. The blocked bead/antibody mixtures
were added to lysates which had been pre-cleared with unconjugated protein G beads and
incubated on a rotating platform for 1hr at 4C. The incubated beads were washed with
PBS five times and bound proteins were eluted by the addition of 1X Laemmli sample
buffer containing 5% β-mercaptoethanol and incubating in a boiling water bath for 10
minutes. The samples were then subjected to SDS-PAGE (10% acrylamide, Life
Technologies), followed by electrophoretic transfer onto a PVDF membrane.
4.3.6 Mutational Analyses. The effect of cellular mA3 on the mutation of viral
transcripts was assessed in 3T3 or 3T3/mA3 cells infected with either gGag+ or gGagMuLVs that had been biologically cloned by endpoint dilution using the FIA (Chapter 3).
Cells were infected with the respective viruses and twenty-four hours after infection the
cells were lysed and newly synthesized viral sequences amplified using the Extract and
Amp PCR kit (Sigma) according to the manufacturer‟s instructions. The primers used for
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amplification

were

the

(TTGAGAGAGTACACTAGTC)

env
as

gene
the

primers

forward

primer

with
and

CasFrKP6805
CasFrKP7886RC

(TCTGTTCCTGACCTTGATC) as the reverse primer. PCR products were resolved on a
3% 3:1 NuSieve agarose gel and were purified using a Zymo gel purification kit (Zymo)
according to manufacturer‟s instructions. Purified PCR products were cloned into the
PCR4-TOPO vector using the TOPO TA Cloning Kit for Sequencing (Invitrogen)
according to the manufacturer‟s instructions and sequenced using the env primers. For
virion mutation analysis, virions were harvested from tissue culture supernatant of 3T3 or
mA3/3T3 cells infected with the gGag+ or gGag- viruses. The transcripts from lysed
purified virions were generated using the Colormetric reverse transcription kit (Roche).
Reaction conditions were followed according to the manufacturer's instructions; however,
random hexamers and unlabeled nucleotides were used in place of the primers and
nucleotides provided with the kit. Transcripts generated in this reaction originated from
the virion RT with the virion genome as the template.

The transcripts were amplified,

purified, cloned and sequenced as described above. The influence of virion-associated
mA3 on the mutation of viral transcripts was assessed after infection of naive Mus dunni
cells with gGag+ or gGag- viruses harvested from 3T3 or 3T3/mA3 cells. Twenty-four
hours after infection the Mus dunni cells were lysed and viral sequences amplified,
purified, cloned and sequenced as described.
Groups of sequences generated in these analyses were compiled and compared in
the DNAstar Lasergene program, SeqMan. All sequences were trimmed from either end
to minimize ambiguity and to yield a 755 bp sequence for uniform comparisons.
Redundant mutations occurring at the same position in two or more clones likely
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originated from pre-existing heterogeneity in the virus stock or by amplification of the
same proviral transcript (see chapter 2). Therefore, coincident mutations were eliminated
from the analysis.

Mutation rates for each type of point mutation (e.g., G-to-A

transitions) were calculated as the frequency per nucleotide of that change in each
sequenced clone. The mutation rates for each type of mutation for each clone were
averaged to give the mean mutation rate as well as the standard error for that specific type
of mutation. The overall mutation rate per clone was calculated as the frequency per
nucleotide of all mutations in each clone. The overall mutation rate for the data set was
calculated by averaging the rate for each clone to give the mean overall mutation rate and
the standard error.
4.3.7 Accumulation of proviral transcripts in infected cells. To determine the
effect of cellular mA3 on reverse transcription, 3T3 and 3T3/mA3 cells were infected
with gGag+ and gGag- viruses. Cellular DNA was isolated at eight and twenty-four hours
post-infection using the AquaGenomic DNA isolation kit (Aquaplasmid) according to the
manufacturer‟s instructions. Levels of viral- specific DNA were then determined by
semi-quantitative PCR using primers specific for the viral env gene (CasFrKP6805 and
CasFrKP7886RC). PCR products of the gapdh gene were amplified using Gapdh-152f
AACGACCCCTTCATTGAC (forward) and Gapdh-342r TCCACGACATACTCAGCAC
(reverse) and used as internal controls. Evaluation of the influence of virion-associated
mA3 on the level of transcripts in infected cells was assessed by infection of naïve Mus
dunni cells with gGag+ and gGag- viruses harvested from 3T3 or 3T3/mA3 cells. DNA
from infected cells was isolated and evaluated for viral transcript levels as described
above. In these experiments Mus dunni cells were infected with virus stocks normalized
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using the major structural virion protein, p30. A standard dilution curve was generated
using amplification of a plasmid containing the sequence of the gGag+ MuLV with the
env gene primers. The standard dilution curve was used to quantify transcript levels by
densitometry using the AlphaView software program (Cell Biosciences).
4.3.8 Localization of gGag and mA3 in infected cells. 3T3 or 3T3/mA3 were
seeded on cover slips and infected with gGag+, gGag- MuLVs, or mock-infected. Samples
were collected at 6, 12, 24, and 48 hours post infection. Cells were fixed for 15 minutes
in 3.7% formaldehyde, washed in PBS, and permeabilized in 0.5% Triton X-100 for 15
minutes. Samples were blocked with 10% BSA in PBS for 30 minutes, followed by
incubation for 30 minutes with monoclonal rat anti-HA (1:100) and a 30 minute
incubation with polyclonal rabbit anti-glycosylated gag (1:250) in 3% BSA in PBS.
Samples were then washed in PBS and incubated with DylightFluor (Jackson
Laboratories) 488-conjugated goat anti-rat IgG (1:250) and DylightFluor (Jackson
Laboratories) 594-conjugated goat anti-rabbit IgG (1:250) with Hoechst 33342
(1:100,000) as a nuclear counterstain. Samples were washed in PBS followed by rinsing
in ddH2O. Processed coverslips were mounted onto slides with Mowiol (Polysciences)
and fluorescence images were collected via sequential scanning on a Zeiss 510 Meta
scanning laser confocal microscope.
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4.4 Results
4.4.1 mA3 is not depleted from infected mA3 cells in a gGag-dependent manner
In a previous report we observed that mA3 inhibited the replication of a gGagvirus but not a gGag+ virus101. The Vif protein of HIV blocks the action of hA3G by
inducing its rapid proteolytic degradation through ubiquitination and transport to the
proteosome34.

It was therefore of interest to determine if MuLVs utilize a similar

mechanism to counteract the antiviral activity of mA3. 3T3/mA3 cells were infected
with either gGag+ or gGag- MuLVs. Forty-eight hours after infection, cells were
harvested and mA3 levels evaluated by immunoblot analysis. The levels of mA3 were
quantified by comparing signal intensities of mA3 to GAPDH or β-Actin signal
intensities using ImageQuant software (GE).
Figure 4.1. Determination of depletion in
infected 3T3/mA3 cells. 3T3/mA3 cells were
infected with either gGag+ or gGag-. Fortyeight hours after infection, cells were harvested
and analyzed via immunoblot analysis. The
amount of depletion was quantified by
comparing signal intensity to β-Actin signal
intensity using ImageQuant software (GE).

A reduction in the level of mA3 was not observed in gGag+ MuLV infected 3T3/mA3
cells compared to cells infected with the gGag- virus or mock infected cells (Figure 4.1),
indicating that mA3 is not depleted from infected cells in a gGag-dependent manner.
4.4.2 Interactions between gGag and mA3 are not detected in infected cells
The MuLV gGag protein is synthesized to levels equivalent to the structural Gag
proteins in infected cells54 and may serve to bind and deactivate mA3. To determine if
there are binding interactions between mA3 and gGag in infected cells, 3T3/mA3 cells
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were infected with either gGag+ or gGag- MuLVs or mock-infected. Forty-eight hours
after infection, cells were lysed and immunoprecipitated with anti-HA or anti-gGag
antibodies. Immunoprecipitated complexes were analyzed by immunoblot analysis. Both
of the antibodies precipitated their respective proteins, however, coprecipitation of mA3
and gGag was not observed with either antibody in lysates of infected 3T3/mA3 cells
(Figure 4.2).

Figure 4.2. Immunoprecipitation of infected
3T3/mA3 cells. Infected 3T3/mA3 cell lysates
were immunoprecipitated with a monoclonal
anti-HA antibody or the polyclonal rabbit antiglycosylated gag antibody. Immunoprecipitated
samples were eluted by addition of running
buffer and boiling for 10 minutes. The samples
were then subjected to SDS-PAGE followed by
transfer onto PVDF membranes. Membranes
were analyzed by immunoblot technique.

4.4.3 Localization of mA3 and gGag in infected cells
It is possible the reaction conditions used in the immunoprecipitation reactions
may disrupt weak interactions or that interactions between the mA3 and gGag proteins
are transient.

Human APOBEC3G has been suggested to associate with lipid rafts in

cells116. An association of mA3 with lipid rafts has not been demonstrated, however
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gGag has been reported to associate with lipid rafts during the process of virus budding
from the cell 96,123 . It was of interest to determine where mA3 and gGag localize in an

Figure 4.3. Localization of mA3 and gGag in an infected cell. 3T3/mA3 infected with the
gGag+ MuLV. At 6, 12, 24, and 48 hours post infection cells were processed for
colocalization analysis with monoclonal rat anti-HA and DylightFluor 488 conjugated Goat
anti-rat IgG (green) or polyclonal rabbit anti-glycosylated gag IgG and DylightFluor 594
conjugated Goat anti-rabbit IgG (red) with Hoechst 33342 (blue) A). 3T3/mA3 cells infected
with the gGag+ MuLV, processed for colocalization analysis 6, 12, 24 and 48 hours post
infection (40 X). B). 3T3/mA3 infected with the gGag+ MuLV, processed for colocalization
analysis 48 post infection (100X).
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infected cell and determine if there is colocalization of the two proteins at different times
after infection. 3T3 or 3T3/mA3 cells were grown on cover slips and infected with
gGag+, gGag- MuLVs or mock-infected. At different times after infection samples were
processed for localization analysis. In agreement with other reports, mA3 was localized
predominantly in the cytoplasm whereas gGag occupied a perinuclear location suggesting
processing in the endoplasmic reticulum (Figure 4.3B). At no time after infection did
gGag appear to be colocalized with mA3 in gGag+ MuLV-infected cells (Figure 4.3A).
Taken together with the immunoprecipitation studies, these findings suggest that gGag
and mA3 do not directly interact in an infected cell.
4.4.4 Localization of gGag and mA3 in virions
In an earlier report, both mA3 and gGag were identified as virion components in
gGag+ virions released from mA3-expressing cells101. Differences in localization or
association in the virion with gGag may have an influence on how virion-associated mA3
exerts its activity in an infection. It is unknown where gGag exists in the virion and the
location of mA3 in the virion is unclear, though one report suggested that some mA3
exists in the viral core162. If gGag is a type II transmembrane protein as reported65,147, it
might be expected to be located on the surface of the virion as a component of the
envelope and thus be unavailable to interact with mA3. To determine the localization of
gGag and mA3 in the virion, 3T3/mA3 cells were infected with gGag+ viruses. Purified
virion samples were pelleted through a 10-30% sucrose step gradient in which the 10%
sucrose layer contained the non-ionic detergent, IGEPAL. Non-ionic detergents such as
IGEPAL or NP-40 have been used in similar gradients in several reports to separate viral
cores from the membrane bound virion components3,136,140,162.Virion pellets were
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analyzed via immunoblot techniques. Under conditions in which the virion membrane
envelope protein gp70 (SU) is completely stripped from the virion, both mA3 and gGag
proteins persist in the sedimented material suggesting that both proteins are components
of the viral core. Thus, their virion localization does not preclude an interaction between
them (Figure 4.4). It is noteworthy that conditions that result in the loss of the SU protein
from virions also results in the loss of substantial levels of the major virion core protein,
p30 (CA) and may reflect a similar loss of mA3 and gGag from the virion core during
their fractionation162.

Figure 4.4. Isolation of viral cores from
virions produced in mA3 cells. gGag+ or
gGag- MuLVs from mA3/3T3 cells were
purified and sedimented through a 10-30%
sucrose step gradient in PBS with IGEPAL in
the 10% layer of the sucrose gradient at a
concentration of 5%. Resulting pellets were
analyzed by immunoblot technique with
monoclonal
anti-HA
HRP-conjugated
antibody, polyclonal rabbit anti-gGag HRPconjugated antibody, polyclonal goat anti-gp70 antibody or an HRP-conjugated
monoclonal anti-capsid (p30) antibody (mAb
18-7).

4.4.5 Interactions between gGag and mA3 in virions
In our earlier studies, we observed that virions that have incorporated mA3
exhibit a lower infectivity and that this inhibition is gGag-dependent101. The finding that
both mA3 and gGag exist in the virion core suggests the possibility of an interaction
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between mA3 and gGag in the virion that was not observed in the cell. Virions were
collected from mA3 cells infected with gGag+ or gGag- MuLVs 48 hours post infection.
The virions were lysed and immunoprecipitated with anti-HA or anti-gGag conjugated to
protein G magnetic beads. The immunoprecipitated samples were analyzed by
immunoblotting procedures. An antibody to mA3 was able to precipitate mA3 but did
not result in the coprecipitation of gGag (Figure 4.5). There are a number of possible
explanations for the inability to demonstrate an interaction between mA3 and gGag using
the mA3 antibody.

These include stoichiometric differences, stearic hindrance, or

differences in antibody affinities.

In contrast, the reciprocal experiments clearly

demonstrated that the mA3 protein was precipitated by antibodies to gGag in virions
containing gGag but not from gGag- virions indicating an interaction between mA3 and
gGag in the virion (Figure 4.5).

Figure 4.5. Immunoprecipitation of mA3
containing virions. gGag+ or gGag- MuLVs
from mA3/3T3 cells were purified and
immunoprecipitated with Protein G beads
conjugated with monoclonal anti-HA antibody
or the polyclonal rabbit anti-glycosylated gag
antibody Resulting complexes were analyzed
by immunoblot technique with monoclonal
anti-HA HRP-conjugated antibody or the
polyclonal rabbit anti-gGag HRP-conjugated
antibody.
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4.4.6 The cellular mA3 protein does not induce G-to-A hypermutation in viral
transcripts
mA3 has been reported to induce hypermutation in the reverse transcripts of
several retroviruses including the XMRV and AKV MuLVs as well as HIV resulting in a
reduction of infectivity14,74,110. Our previous report revealed that both cellular and virionassociated mA3 inhibited the gGag- MuLV but not the gGag+ MuLV101. It is possible that
this inhibition was the result of deamination mediated by mA3. To investigate this
possibility, viral transcripts from 3T3/mA3 cells infected with gGag+ or gGag- viruses
were amplified by PCR, cloned and sequenced to determine point mutations incurred
during infection. Parallel experiments were performed in 3T3 cells devoid of mA3.
DNA was isolated early (24 hours) after infection to limit the analyses to transcripts that
had undergone a single replication cycle. No evidence of G-to-A hypermutation was
observed, nor was there a significant difference in the G-to-A mutation rate between
transcripts generated in gGag+ or gGag- MuLV-infected cells.

Surprisingly, a

significantly higher overall point mutation rate was observed in transcripts from
3T3/mA3 cells infected with the gGag- virus compared to 3T3/mA3 cells infected with
the gGag+ MuLV while a significant difference in overall mutation rate was not observed
in 3T3 cells (Figure 4.6). Examination of the mutation rates for all possible base changes
did not suggest the prevalence of a particular type of mutation contributing to the overall
mutation rate difference (data not shown). These results suggest that mA3 may exert an
influence on reverse transcription independent of cytidine deaminase activity.

66

Figure 4.6. The mutation rates of samples exposed to cellular mA3. For analysis of
cellular mA3s activity, 3T3 or 3T3/mA3 cells were infected either gGag+ or gGag-.
Twenty-four hours after infection cells were lysed and viral sequences amplified by
PCR, cloned and sequenced. The mutation rates for each clone were averaged to give the
mean mutation rate as well as the standard error. gGag+ NIH3T3/mA3=81 clones, gGagNIH3T3/mA3=42 clones, gGag+ NIH3T3=63 clones, gGag- NIH3T3=78 clones.
4.4.7 Mutation rates in transcripts generated by cell-free virions
Uracil-containing DNA is rapidly degraded in cells by apurinic/apyrimidinic
endonuclease (APE)13,105,185.

The cytidine deaminase activity of mA3 results in a

conversion of cytidine to uracil in the single-stranded transcripts generated by RT and it
is possible that such transcripts are rapidly eliminated. If this were to occur it would bias
the analyses of the mutation rate in infected cells and hypermutation would be apparent in
a reaction without cellular factors.

To determine if cellular factors mask the true

deamination rate, cell-free virions produced from mA3 cells infected with gGag+ or
gGag- MuLVs were isolated and employed in endogenous RT reactions to generate
transcripts in the absence of cellular factors.

The determination of the G-to-A and

overall mutation rates in the endogenous reverse transcription reactions did not reveal
evidence of hypermutation nor were significant differences in mutation rates observed
between the samples (Figure 4.7). Taken together, these mutational analyses suggest that
cytidine deamination is not the main mechanism used by mA3 to inhibit MuLVs in a
gGag-dependent manner.
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Figure 4.7. The mutation rates of samples in the endogenous viral reactions. For
analysis of mA3s activity in a cell free environment, 3T3 or 3T3/mA3 cells were
infected either gGag+ or gGag-. Virions were collected and used in cell-free
endogenous RT reactions. Viral sequences amplified by PCR, cloned and sequenced.
The mutation rates for each clone were averaged to give the mean mutation rate as well
as the standard error. gGag+ purified from NIH3T3/mA3=152 clones, gGag- purified
from NIH3T3/mA3=169 clones, gGag+ purified from NIH3T3=164 clones, gGagpurified from NIH3T3=156 clones.
4.4.8 Mutation rates in transcripts induced by virion-associated mA3 in infected
cells
It has been reported that cellular hA3g reduces the level of accumulated reverse
transcripts in infected cells but does not induce G-to-A hypermutation29. In contrast,
virion-associated hA3g induces G-to-A hypermutation upon infection26,27. To determine
if virion-associated mA3 exerted a similar affect, naïve Mus dunni cells were infected
with viruses released from 3T3 or 3T3/mA3 cells. Twenty-four hours post infection viral
transcripts were analyzed for point mutations as described above.

No evidence of

hypermutation was apparent nor were significant differences observed in the G-to-A
mutation rate or in the overall mutation rates between the samples (Figure 4.8). It is
noted that the experiments determining the mutation rates of virion-associated mA3 are
complicated by the procedures employed to generate the viruses. Progeny viruses were
obtained after infection of 3T3 cells or 3T3/mA3 and incurred point mutations during this
process. Although precise determinations of mutation rate are compromised by this
process, hypermutation as a result of virion-associated mA3 would be apparent.
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Figure 4.8. The mutation rates of samples exposed to virion-associated mA3. For
analysis of virion-associated mA3s activity, 3T3 or 3T3/mA3 cells were infected either
gGag+ or gGag-. Virions were collected and used infect Mus Dunni cells. Cells were
lysed and viral sequences amplified by PCR, cloned and sequenced. The mutation rates
for each clone were averaged to give the mean mutation rate as well as the standard
error. gGag+ from NIH3T3/mA3=87 clones, . gGag- from NIH3T3/mA3=67 clones,
gGag+ from NIH3T3=84 clones, . gGag- from NIH3T3=21 clones
4.4.9 Cellular mA3 reduces viral transcript accumulation in a gGag-dependent
manner
APOBEC3 proteins have been reported to utilize hypermutation-independent
mechanisms to inhibit retroviral replication

4,29,79,100

. In this regard, a partial inhibition of

M-MuLV by mA3 was reportedly associated with a reduction in the total amount of viral
DNA accumulated in the cell18. In our experiments cellular mA3 was shown to inhibit
viral replication in a gGag-dependent fashion101.

It is possible that mA3 exerts an

inhibitory effect on reverse transcription resulting in reduced levels of viral transcripts in
infected cells. To determine if gGag influences the accumulation of viral DNA in infected
cells, 3T3 or 3T3/mA3 cells were infected by gGag+ or gGag- MuLVs and the level of
accumulated transcripts determined. At 24 hours after infection, PCR amplification of
viral DNA revealed a striking reduction in the transcript levels in 3T3/mA3 cells infected
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with the gGag- virus compared to levels found in 3T3 cells (Figure 4.9B). In contrast, no
significant reduction in transcript levels between the two cell lines was observed after
infection by the gGag+ virus.

These results suggest a function of cellular mA3 that is

inhibited by the presence of gGag that correlates with the reduction of infectivity.

Figure 4.9. Quantification of viral transcripts in infected cells expressing mA3.
gGag+ and gGag- viruses were used to infect 3T3 and mA3 cells. Eight (B) and twentyfour (A) hours after infection cells were lysed and viral sequences amplified by PCR.
GAPDH PCR products were used as loading controls and samples were quantitated using
a standard curve.
At 24 hours after infection it is expected that most viral DNA in the cell exists as
integrated proviruses in the host genome. Thus, the reduction in viral DNA at this time
could reflect processes that occurred after reverse transcription rather than an effect of
mA3 on reverse transcription itself. To examine this possibility, viral transcript levels
were determined 8 hours after infection. At this time, very little, if any, viral DNA would
be in the form of integrated proviruses and would more closely reflect immediate
products of reverse transcription. These analyses also revealed a significant decrease in
the level of transcripts in 3T3/mA3 cells compared to 3T3 cells when infected with the
gGag- MuLV (Figure 4.9A). A similar difference in the level of transcripts in these cells
was not observed upon infection with the gGag+ virus.
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These results suggest that the

reduction in viral transcripts in cells infected by the gGag- virus in the presence of
cellular mA3 is the result of an effect of mA3 on reverse transcription rather than a
subsequent process during infection.
4.4.10 Viral transcript levels in cells infected by viruses containing mA3
Our previous studies indicated that virion-incorporated mA3 is also inhibitory to
infection in a gGag-dependent manner101. In these studies a substantial reduction in the
infectivity of individual virions (specific infectivity) was observed. The experiments
above suggest that the reduction in transcripts of gGag- viruses in the presence of cellular
mA3 occurs at the level of reverse transcription rather than at a later stage of infection. If
the inhibition of specific infectivity is due to inhibition of reverse transcription occurring
at a post-entry stage of infection, then infection of naïve cells by an equal number of
gGag+ or gGag- MuLVs containing mA3 would be expected to result in a reduction of
transcripts of the gGag- compared to the gGag+ virus. Alternatively, it is possible that the
mechanism of inhibition by cellular mA3 differs from that of virion-associated mA3 and
might involve post-transcriptional events. These analyses were undertaken to determine
if the decrease in specific infectivity of mA3-containing gGag- virions observed in earlier
experiments (Chapter 3) was a result of events occurring early in infection, before or
during reverse transcription or, alternatively, at a later stage of infection subsequent to
reverse transcription. To examine this possibility naïve Mus dunni cells were infected
with gGag+ and gGag- MuLVs harvested from 3T3 or 3T3/mA3 cells and normalized to
equal levels of virions. Amplification of viral DNA 24 hours after infection revealed that
viral transcripts were virtually undetectable in cells infected with gGag- MuLVs
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containing mA3 (Figure 4.10). These results are consistent with a process of mA3
inhibition of reverse transcription which is circumvented by gGag.

Figure 4.10. Quantification of viral transcripts in cells infected by virions containing
mA3. gGag+ and gGag- viruses (amount normalized with p30 quantification) from 3T3 or
mA3 cells were used to infect Mus Dunni cells. Cells were lysed after 24 hours and viral
sequences amplified by PCR. GAPDH PCR products were used as loading controls and
samples were quantitated using a standard curve.

4.5 Discussion
In this chapter we investigated the mechanisms of the MuLV gGag-dependent
escape from mA3 antiviral activity. We found in our experiments that mA3 was not
depleted from infected cells. This differs from the way HIV uses its Vif protein to
facilitate the proteolytic degradation of hA3g in infected cells34. Further suggesting the
absence of a direct interaction in an infected cell, neither coimmunoprecipitation nor
colocalization between mA3 and gGag was observed. Thus, an indirect interaction
between mA3 and gGag in an infected cell is hypothesized to be responsible for the
gGag-dependent inhibition of replication seen in mA3 cells.
Our analysis of the localization of gGag in the virion revealed that gGag is
localized within the core along with mA3. This was a surprising result as gGag is
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described as a transmembrane protein in an infected cell and would be expected to be
localized with the envelope65,147. Nonetheless, this colocalization in the virion between
gGag and mA3 could facilitate the abrogation of mA3 inhibitory activity.
Coprecipitation experiments revealed that gGag and mA3 do interact in mature virions.
The importance of this localization and interaction of mA3 and gGag in the virion is
unknown, but may further signify a protective role for gGag from mA3 activity. Further
experimentation will be necessary to delineate the importance of interactions of mA3 and
gGag in the virion.
Previous studies of the action of APOBEC3 proteins on retroviral replication have
predominantly

examined

the

activity

of

virion-associated

hA3G

or

mA317,20,22,23,34,77,96,100,124,126,128,132,179. Our approach enabled the analysis of the action of
mA3 expressed in the cell, which perhaps more closely reflects a natural retroviral
infection.

In our initial studies, cellular mA3 exerted a marked inhibition of virus

infection in a gGag-dependent manner101.

This result was somewhat unexpected

considering that the incorporation of gGag in virions is thought to be quite low63. Here,
the analyses of G-to-A mutation rates of viral transcripts in mA3-expressing cells were
not significantly different between cells infected by the gGag+ or gGag- viruses.
However, a significant increase in the overall mutation rate was observed after infection
by the gGag- MuLV. Further, the level of viral transcripts in mA3-expressing cells was
strikingly reduced when infected with the gGag- virus. These results are consistent with
our results of the effect of cellular mA3 on infectivity.
Our studies have revealed that that virion-associated mA3 reduced the specific
infectivity of virions in a gGag-dependent manner63 which was reflected in levels of viral
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transcripts in infected cells. This observation is not without precedent, as another report
indicated that mA3 may also possess deaminase-independent activity18. While a high
number of G-to-A mutations was not seen in M-MuLV, the transcript levels were reduced
in an amount comparable to the reduction in infectivity18. This suggests that the gGag of
M-MuLV may not completely block the action of mA3. It is noted that analyses of other
MuLV sequences reveal extensive differences in their gGags including deletions and
amino acid substitutions (data not shown).

In this regard, XMRV exhibits termination

codons in the sequence encoding gGag and has been reported to be susceptible to the
action of mA3.
Inhibition of MuLVs by cellular or virion-associated mA3 occurs in a gGagdependent manner. The precise mechanism by which virion gGag abrogates the action of
mA3 is unclear. Considering the high infectivity to particle ratios reported for many
retroviruses165, it is possible that a large number of “non-infectious” virions may
nonetheless enter the cell and provide a sufficient amount of gGag protein to effect
inhibition of cellular mA3. Alternatively gGag present in the virion could protect the
virus from inactivation by mA3. Such an effect could be operative to protect against both
cellular and virion-associated mA3. Our results strongly suggest that the mechanism of
inhibition by mA3 involves an effect on reverse transcription of the viral genome and is
largely independent of G-to-A mutation. It is possible that gGag exerts a stabilizing effect
during reverse transcription or perhaps in the integrity of other virion components. It is
also possible that gGag acts in a stearic manner preventing an interaction of mA3 with
the RT or viral RNA. In the absence of gGag, there is an increase in the overall point
mutation rate and a reduction of the level of transcripts in infected cells in the presence of
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mA3. These two effects may be linked, thereby causing both a decrease in transcription
efficiency as well as a decrease in RT fidelity. Further studies will help elucidate the
protective effect of gGag against mA3 activity.
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CHAPTER 5: Summary
5.1 Discussion
HIV evades the action of hA3G through expression of an accessory protein, Vif,
however the means by which exogenous MuLVs evade the action of mA3 was
unclear28,162. We have shown that gGag acts as an antagonist of cellular and virionassociated mA3 in vitro and have found gGag to be essential for in vivo replication in
mA3 expressing mice. The mechanistic basis for these observations is largely
independent of G-to-A mutation but is associated with a reduction of reverse transcripts
in infected cells.
Inhibition of infectivity by mA3 was observed in two distinct contexts in our in
vitro system: during the initial infection in which viruses devoid of mA3 infect cells
expressing mA3 (cellular mA3); and during the subsequent infection in which viruses
containing mA3 (virion-associated mA3) infect naïve cells not expressing mA3.
Inhibition by cellular mA3 is not without precedent. It has been reported that M-MuLV123
and mouse mammary tumor virus138 are partially inhibited by cellular mA3. HIV has also
been reported to be inhibited by cytoplasmic hA3g196. Nevertheless, it was unexpected
that cellular mA3 exerted a gGag-dependent effect on MuLV infectivity in the absence of
virion-associated mA3 considering that the level of gGag incorporated into the virion is
low compared to that which is expressed in an infected cell54,63. Furthermore, the small
amount of gGag in the virion would be expected to associate with the viral envelope as a
type 2 transmembrane protein65,147. Our experiments involving the localization of gGag
in the virion shows clearly that it is associated with the virion core. There are many
possible functional consequences of this localization. One of these is that gGag may serve
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to stabilize the structure of the virion. It has been reported that gGag is involved in virion
release and that gGag- M-MuLV exhibits an abnormal morphology during virion
budding121. Mature virions also differed from the wild-type virions by envelope lipid
content but did not exhibit detectable morphological differences. In agreement with a
number of other studies with different MuLVs, the gGag-deficient M-MuLV was not
replication-defective in vitro but replication was severely limited in vivo121.
A number of mechanisms by which cellular mA3 might interact with gGag were
examined in these studies. The HIV-1 Vif protein mediates the degradation of hA3G in
infected cells and it was possible that the presence of gGag might lead to mA3
degradation28,162. However, no significant difference in the level of mA3 expression was
detected in the presence or absence of gGag. Thus, viral gGag does not lead to the
proteolytic degradation of mA3 in vitro. The inhibition of cellular mA3 by gGag may
involve a direct interaction of the proteins that delays or prevents mA3 from exerting its
effect. In this regard, immunoprecipitation experiments using antibodies directed at
either protein did not result in coprecipitation of the proteins. It is possible that
interactions between cellular mA3 and gGag may exist but be too weak or fleeting to be
detected by immunoprecipitation techniques. If the proteins do interact in infected cells,
it is possible that colocalization to the same cellular compartment might be detected by
confocal microscopy; however, no specific colocalization of the two proteins was
detected when examined at various times after infection. In the absence of evidence
supporting a direct interaction, it was surmised that there may be an indirect interaction
between cellular mA3 and viral gGag that enables the virus to escape the activity of mA3.
Although the mutation data did not reveal a substantial cytidine deaminase
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activity for cellular mA3, a higher overall mutation rate was observed with gGag- than
with gGag+ MuLVs. This may reflect a functional role of gGag in promoting the fidelity
or stability of reverse transcription and counteracting a destabilizing action of mA3.
Such a role is consistent with the location of gGag in the virion and suggests it may
interact with RT, RNA or other virion components in the reverse transcription complex to
stabilize the reverse transcription reaction. It has been reported that APOBEC3 proteins
exert deaminase-independent inhibitory activity on retroviral replication, though the
mechanism by which it is accomplished is poorly defined. In this regard a recent study
reported that M-MuLV was partially inhibited by mA318. An elevated G-to-A mutation
rate was not observed, however, the transcript levels were reduced in an amount
comparable to the reduction in infectivity. Similarly, we observed a striking inhibition of
viral transcription levels after infection of cells with the gGag- virus. While the gGag+
transcript levels remained consistent between 3T3/mA3 and 3T3 cells, the gGagtranscript levels were significantly reduced in the presence of mA3. A number of studies
have reported varying susceptibilities of MuLVs to mA3110,123,162,188 . Differences in the
susceptibility of MuLVs to inhibition by cellular mA3 could reflect differences in the
efficacy of their respective gGags to counteract mA3. In this regard, a comparison of the
gGags of different MuLVs reveals subtle to extensive differences which include deletions
as well as amino acid substitutions (data not shown).
We observed that progeny virions released from mA3 expressing cells were also
inhibited in a gGag-dependent manner when tested on cells not expressing mA3. It is
possible that both gGag+ and gGag- MuLVs incorporate mA3 into virions at similar levels
but that the incorporation of mA3 is qualitatively different between the MuLVs.
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The

location or association of mA3 with virion components may be altered in response to the
presence of gGag. The observation that mA3 is located in the virion core for both the
gGag+ and gGag- MuLVs argues against this possibility. The presence of both gGag and
mA3 in the virion core may allow for an interaction between the two proteins.

In

contrast to the immunoprecipitation analyses in infected cells, coprecipitation of mA3
and gGag was observed in the virion. The proximity of mA3 and gGag to each other in
the virion or the presence of a binding intermediate, such as the RNA genome or other
binding partners may facilitate coprecipitation in the virion but not in the cell. Further
experimentation will reveal if viral RNA or other proteins are associated with mA3 and
gGag.
The binding interaction observed in these analyses may function to prevent mA3
from exerting its antiretroviral activity on the virus during reverse transcription upon
infection. No statistically significant differences of the mutation rates were observed
between any of the viruses regardless of virion incorporation of mA3 or gGag. However,
the transcript level was severely reduced in Mus dunni cells infected with the gGagviruses produced from 3T3/mA3 cells. In these experiments the level of virus used to
infect the Mus dunni cells was adjusted to the number of virions rather than the
infectivity. Assuming that the presence of mA3 in the absence of gGag does not alter the
initial events of viral receptor binding and fusion to enter the cells, it is likely that the
process of reverse transcription was altered in the infected cells. Conversely, in cells
infected with the wild-type virus possessing gGag and mA3, inhibition was presumably
prevented by the interaction of gGag and mA3.
The results of the in vitro studies were corroborated in our in vivo investigations.
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There was a striking inhibition of replication in vivo of the gGag- MuLV compared to the
gGag+ MuLV in mice expressing mA3.

In mice lacking mA3, the level of Gag-

replication was restored to the high levels of gGag+ MuLV. These results were obtained
in both the 129/Ola and C57BL/6 genetic background. Development of reagents, such as
a specific mA3 antibody, will facilitate in vivo studies as one could determine beyond
mRNA levels the amount and type of mA3 expressed in tissues and the amount that is
incorporated into virions. The development of specific tags and/or refinements in the
purification of virions from mice may also make it possible to more precisely determine
the amount of gGag incorporated into virions.
5.2 Future directions
Based on the localization of gGag in the virion core, gGag may serve a function in
stabilizing the mature virion or the reverse transcriptase complex. To this end, a recent
report indicated that gGag exhibits some functional similarities to the Nef protein of
HIV149. Nef is an accessory protein of HIV that exhibits many different functions
including increasing the efficiency of reverse transcription168. Nef is incorporated into
virions and facilitates replication both in vitro and in vivo19,94,95,144. Nef-deficient viruses
exhibit reduced infectivity which can be restored by complementation with gGag.
Indeed, the complementing activity of gGag was discovered in cells which had been
inadvertently infected with an MuLV149. It is unknown if Nef has an influence on the
action of APOBEC3 proteins nor is it clear if Nef can complement the effect of gGag on
MuLV replication Further studies of the action of Nef may provide insight into the
precise mode of action of gGag on the activity of mA3.
The susceptibility of the gGag- MuLV to cellular mA3 may occur by an indirect
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mechanism. In this regard, it has been reported that gGag is involved in virion release
and that gGag- M-MuLV exhibits an abnormal morphology during virion budding121. It is
conceivable that mature virions may be altered from an mA3-resistant to an mA3susceptible phenotype. If an altered mA3-sensitive phenotype exist, then it may be
possible to restore it by infecting cells that contain a gGag construct or by superinfecting
cells with another MuLV encoding a functional gGag. Indeed, Low et al121 showed that
expressing a gGag construct in a retroviral packaging cell line restored the gGag- budding
virion phenotype to a more common spherical one. It is of interest to determine if the
expression of gGag in a cell would restore the infectivity of progeny virions on mA3
expressing cells. Further, if complementation in trans could be demonstrated, it might be
possible to compare the efficacies of different MuLV gGag proteins.
In the in vitro studies, the gGag+ MuLV was not inhibited, however, there has
been a number of studies that

report partial to marked inhibition of other gGag+

MuLVs109,122,162,187. One report compared the inhibitory effects of mA3 on M-MuLV and
AKV MuLV. AKV was inhibited to a greater extent than M-MuLV108. Inhibition of AKV
by mA3 exhibited G-to-A mutations whereas M-MuLV did not107,162. The susceptibility
of MuLVs to inhibition by mA3 could represent a difference in the efficacy of gGags to
counteract mA3.

Comparing the gGag sequences of multiple MuLVs revealed

differences in their amino-terminal fragments. It is of interest to determine if the
inhibition of mA3 by gGag of viruses utilized in this study can be generalized to other
gGag- viruses. This could provide insight into differences in the activities of gGag
proteins from different sources. As mentioned above, it may also be possible to directly
compare efficacies of different MuLVs through complementation studies.
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Some studies have noted that there are allelic differences between different mouse
strains in the both the levels and isoforms of expressed mA3. Some mice express the full
length protein, while others express a Δ exon 5 or a Δ exon 2 splice variant111,139,162,163.
There are conflicting reports on the inhibitory activities of these variants. In our studies,
there was a gGag-dependent inhibition in 129/Ola mice, which predominately produce
the full-length version, and in C57BL/6 mice, which predominately produce the Δ exon 5
splice variant. It is unknown if there are differences in the activities in vivo as the
expression levels are different between mouse strains. In order to address this issue, it
will be necessary to conduct parallel in vitro studies using cells expressing full length
mA3 as well as the spice variant forms of the protein.
During the course of these investigations it was noted that some uninfected mA3-/mice developed a proliferative disease at 6 to 8 months of age. Spontaneous proliferative
diseases in mice are often accompanied by the expression of endogenous retroviruses. It
will be of interest to determine if the expression of endogenous viruses is demonstrable in
mA3-/- mice that have developed proliferative disease.
In closing, the studies conducted for this dissertation are of particularly interest in
light of recent reports indicating cross-species retroviral infections from mouse to
humans120,166,193. In some studies, these infections are evidenced by the detection of
endogenous gGag-deficient MuLVs. Infection of mice by gGag+ viruses may inhibit the
activity of mA3 and facilitate the mobilization of endogenous MuLVs through
pseudotyping. Certain MuLVs such as amphotropic and xenotropic MuLVs encode intact
gGag proteins and can infect humans. Pseudotyping of endogenous MuLVs by these
viruses could account for the transmission of endogenous gGag-deficient MuLVs.
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